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CNS Penetration of Tyrosine Kinase Inhibitors in Mouse Models
Abstract
For the past three decades, advances in the treatment of central nervous system (CNS) tumors such as
malignant glioma have only been modest. One particular challenge facing treatment of brain tumors is
the delivery of therapeutically effective concentrations of anti-cancer agents to the target site in the brain.
The sanctuary of the brain is protected by several barrier systems such as the blood-brain barrier (BBB)
and the blood-cerebrospinal fluid barrier (BCSFB). These barriers restrict the passage of anti-cancer drugs
into the brain via several protective mechanisms.
In the present study, we used cerebral microdialysis sampling, a technique for sampling unbound
molecules in brain extracellular fluid (ECF) via semi-permeable probe, to assess the role of murine ATP
Binding Cassette (ABC) transporters Bcrp1, P-gp, and Mrp4 in CNS penetration of molecularly targeted
agents under investigation for treatment of malignant glioma. We choose the specific inhibitor of
epidermal growth factor receptor (EGFR), erlotinib (TarcevaTM), and the specific inhibitor of plateletderived growth factor receptor (PDGFR), crenolanib, as examples of tyrosine kinase inhibitors currently
tested for treatment of malignant glioma. Given the poor microdialysis probe recovery of these lipophilic
molecules, we enhanced their recovery by including an affinity-based trapping agent, 10%
hydroxypropylbetacyclodextrin (HPBCD), in the perfusate. Using this technique, we studied erlotinib and
its major metabolite, OSI-420, penetration in control and transporter-deficient mice. We showed that
Bcrp1 is the main efflux transporter preventing erlotinib and OSI-420 penetration in mouse brain.
Intracellular accumulation studies confirmed the role of BCRP in erlotinib and OSI-420 transport. We also
characterized the role of solute carrier transporters in erlotinib and OSI-420 brain accumulation. Our data
show that erlotinib and OSI-420 are substrates for members of the SLC22A family of uptake transporters,
OAT3 and OCT2.
We then sought to characterize the disposition of tyrosine kinase inhibitors in malignant glioma using
cerebral microdialysis. We decided to use a transgenic mouse model that highly recapitulates several
features of the human glioma including tumor histology and genetic profiles. However, the bregma
commonly used as a reference point to place microdialysis cannula does not appear on images derived
by magnetic resonance imaging (MRI), the imaging method used to identify the size and location of the
spontaneously arising tumors. Thus, we realized that a new technique to implant the microdialysis guide
cannula would be necessary. Using angiography studies of mouse brain vasculature and T2-weighted
MRI, we identified the intersection of the midline suture and the rostral rhinal vein on the mouse brain
surface as a reference point for implanting the microdialysis cannula. This point correlated with the
intersection between the midline and the olfactory bulb/frontal lobe border visualized on T2- weighted
MRI. Our method allowed for accurate placement of microdialysis cannula in tumors developing in several
regions of the mouse brain.
While cerebral microdialysis is commonly used to monitor CNS disposition of single anti-cancer drug at a
time, the feasibility of simultaneous sampling of multiple anti-cancer agents via cerebral microdialysis
has not been reported. However, combining anti-cancer drugs represents a promising strategy for
treatment of resistant CNS tumors, as malignant glioma. Given the role played by EGFR and PDGFR in
providing multiple inputs for sustaining glioma cell survival and proliferation, combining inhibitors of
EGFR (erlotinib) and PDGFR (crenolanib) represents a promising treatment strategy for these tumors. The
goal of our last set of studies was to optimize microdialysis conditions to sample crenolanib and erlotinib
as single agents or in combination from tumor ECF in a xenograft mouse model of glioma. By including
10% HPBCD in the perfusate, probe recovery of both erlotinib and crenolanib was significantly increased.
To estimate probe recovery we used the zero-flow rate (ZFR) which estimated stock concentrations with
15% accuracy. The enhanced recovery achieved by including HPBCD coupled with sensitive analytical

techniques allowed us to determine crenolanib and erlotinib penetration in tumor ECF under steady state
conditions. No significant differences were observed in drug penetration between groups treated with
single agent or those treated with both drugs.
In conclusion, we developed techniques to improve microdialysis probe recovery of lipophilic agents
administered as single agents or in combination. We also developed an MRIguided method to implant
microdialysis cannula in a spontaneous glioma murine model. These techniques enhance our ability to
perform microdialysis studies on a large spectrum of anticancer agents in clinically relevant murine
models. Using the developed techniques, we identified efflux and uptake transporters that regulate
erlotinib CNS disposition. We evaluated the extent of erlotinib and crenolanib penetration in malignant
glioma models. Our results shed more light on the extent of tumor penetration of two tyrosine kinase
inhibitors currently being tested for treatment of malignant glioma.
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ABSTRACT
For the past three decades, advances in the treatment of central nervous system
(CNS) tumors such as malignant glioma have only been modest. One particular challenge
facing treatment of brain tumors is the delivery of therapeutically effective concentrations
of anti-cancer agents to the target site in the brain. The sanctuary of the brain is protected
by several barrier systems such as the blood-brain barrier (BBB) and the bloodcerebrospinal fluid barrier (BCSFB). These barriers restrict the passage of anti-cancer
drugs into the brain via several protective mechanisms.
In the present study, we used cerebral microdialysis sampling, a technique for
sampling unbound molecules in brain extracellular fluid (ECF) via semi-permeable
probe, to assess the role of murine ATP Binding Cassette (ABC) transporters Bcrp1,
P-gp, and Mrp4 in CNS penetration of molecularly targeted agents under investigation
for treatment of malignant glioma. We choose the specific inhibitor of epidermal growth
factor receptor (EGFR), erlotinib (TarcevaTM), and the specific inhibitor of plateletderived growth factor receptor (PDGFR), crenolanib, as examples of tyrosine kinase
inhibitors currently tested for treatment of malignant glioma. Given the poor
microdialysis probe recovery of these lipophilic molecules, we enhanced their recovery
by including an affinity-based trapping agent, 10% hydroxypropyl-betacyclodextrin
(HPBCD), in the perfusate. Using this technique, we studied erlotinib and its major
metabolite, OSI-420, penetration in control and transporter-deficient mice. We showed
that Bcrp1 is the main efflux transporter preventing erlotinib and OSI-420 penetration in
mouse brain. Intracellular accumulation studies confirmed the role of BCRP in erlotinib
and OSI-420 transport. We also characterized the role of solute carrier transporters in
erlotinib and OSI-420 brain accumulation. Our data show that erlotinib and OSI-420 are
substrates for members of the SLC22A family of uptake transporters, OAT3 and OCT2.
We then sought to characterize the disposition of tyrosine kinase inhibitors in
malignant glioma using cerebral microdialysis. We decided to use a transgenic mouse
model that highly recapitulates several features of the human glioma including tumor
histology and genetic profiles. However, the bregma commonly used as a reference point
to place microdialysis cannula does not appear on images derived by magnetic resonance
imaging (MRI), the imaging method used to identify the size and location of the
spontaneously arising tumors. Thus, we realized that a new technique to implant the
microdialysis guide cannula would be necessary. Using angiography studies of mouse
brain vasculature and T2-weighted MRI, we identified the intersection of the midline
suture and the rostral rhinal vein on the mouse brain surface as a reference point for
implanting the microdialysis cannula. This point correlated with the intersection between
the midline and the olfactory bulb/frontal lobe border visualized on T2-weighted MRI.
Our method allowed for accurate placement of microdialysis cannula in tumors
developing in several regions of the mouse brain.
While cerebral microdialysis is commonly used to monitor CNS disposition of
single anti-cancer drug at a time, the feasibility of simultaneous sampling of multiple

v

anti-cancer agents via cerebral microdialysis has not been reported. However, combining
anti-cancer drugs represents a promising strategy for treatment of resistant CNS tumors,
as malignant glioma. Given the role played by EGFR and PDGFR in providing multiple
inputs for sustaining glioma cell survival and proliferation, combining inhibitors of
EGFR (erlotinib) and PDGFR (crenolanib) represents a promising treatment strategy for
these tumors. The goal of our last set of studies was to optimize microdialysis conditions
to sample crenolanib and erlotinib as single agents or in combination from tumor ECF in
a xenograft mouse model of glioma. By including 10% HPBCD in the perfusate, probe
recovery of both erlotinib and crenolanib was significantly increased. To estimate probe
recovery we used the zero-flow rate (ZFR) which estimated stock concentrations with
15% accuracy. The enhanced recovery achieved by including HPBCD coupled with
sensitive analytical techniques allowed us to determine crenolanib and erlotinib
penetration in tumor ECF under steady state conditions. No significant differences were
observed in drug penetration between groups treated with single agent or those treated
with both drugs.
In conclusion, we developed techniques to improve microdialysis probe recovery
of lipophilic agents administered as single agents or in combination. We also developed
an MRI-guided method to implant microdialysis cannula in a spontaneous glioma murine
model. These techniques enhance our ability to perform microdialysis studies on a large
spectrum of anti-cancer agents in clinically relevant murine models. Using the developed
techniques, we identified efflux and uptake transporters that regulate erlotinib CNS
disposition. We evaluated the extent of erlotinib and crenolanib penetration in malignant
glioma models. Our results shed more light on the extent of tumor penetration of two
tyrosine kinase inhibitors currently being tested for treatment of malignant glioma.
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CHAPTER 1.
1.1.

INTRODUCTION

INTRODUCTION OF MALIGNANT GLIOMA

1.1.1. Incidence of malignant glioma in adult and pediatric populations
Malignant gliomas are a heterogeneous group of tumors that represents about
70% of adult central nervous system (CNS) tumors (Porter et al., 2010). Approximately
75% of adult gliomas are malignant and can be categorized in two histological
subclasses: anaplastic astrocytoma (AA; World Health Organization WHO grade III) and
glioblastoma multiforme (GBM; WHO grade IV). AA and GBM are collectively referred
to as high-grade gliomas (Fuller, 2008). According to the central brain tumor registry of
the United States (CBTRUS), more than 15,000 adult patients are diagnosed with
malignant gliomas each year (CBTRUS, 2010). Conversely, malignant childhood gliomas
are less common than their adult counterparts, comprising only 15-20% of all childhood
CNS tumors (Broniscer and Gajjar, 2004). The reported incidence of malignant glioma in
both adults and pediatric populations has increased over the past 30 years, partially due to
improved diagnosis with novel imaging modalities such as computed tomography (CT)
and magnetic resonance imaging (MRI) (Legler et al., 1999; Smith et al., 1998).
The anatomical location of these tumors differs in adults and children. In adults,
the majority of malignant gliomas develop in the subcortical white matter of the cerebral
lobes (86%) while the rest develops either in the deep structures of the cerebrum, the
ventricles, or in the cerebellum (Larjavaara et al., 2007). On the other hand, pediatric
gliomas arise from the supratentorial hemispheres or from the pons with the later known
as diffuse brainstem glioma. Supratentorial tumors represent 6-12% of all pediatric
primary CNS tumors while diffuse brainstem glioma accounts for 3-9% (Broniscer and
Gajjar, 2004).
1.1.2. Pathological features of malignant glioma
Depending on the course of the disease, malignant gliomas can be categorized
into primary tumors that develop de novo in the brain with no prior tumor lesion, or
secondary tumors that progress from a low grade to a higher grade astrocytoma (Furnari
et al., 2007). Both adult and pediatric glioma arise predominantly de novo while
secondary tumors are rare (Broniscer et al., 2007a; Furnari et al., 2007; Phuphanich et al.,
1984; Wen and Kesari, 2008).
Malignant gliomas are characterized by their histological heterogeneity. AA
presents clinically with abnormally high mitotic activity and increased cellularity. GBM
also displays similar, or higher, hypercellularity in addition to the highly hypoxic nature
of these tumors (Fuller, 2008). GBM is distinguished from AA via two characteristic
features. First, GBM tumors exhibit micronecrotic foci surrounded with pseudopalisading
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cells (Rong et al., 2006). The second characteristic feature of GBM is its high angiogenic
propensity and intense microvascular hyperplasia (Fuller, 2008; Miyagami and
Katayama, 2005). This hyperplastic vasculature develops in response to pro-angiogenic
growth factors, such as vascular endothelial growth factor (VEGF), that induce
endothelial cell survival, proliferation, and migration (Plate et al., 1994). These
microvessels are structurally and functionally immature, which may contribute to poor
tumor oxygenation and hypoxic microenvironment (Miyagami and Katayama, 2005). The
formation of new blood vessels is crucial for glioma development and progression. This
was supported by reports showing that high degree of microvascular proliferation
correlates with low overall survival in adult glioma patients (Bello et al., 2004; Cheng et
al., 1996; Leon et al., 1996).
An important histological feature of high-grade gliomas is the highly invasive
propensity of glioma cells as they metastasize and invade either along endothelial cells or
more frequently through the brain parenchyma. This diffuse infiltrative phenotype is
referred to as gliomatosis cerebri (Bendszus et al., 2000). Because of this infiltrative
growth pattern, complete surgical resection of malignant glioma is not possible, and local
tumor recurrence is inevitable (Giese et al., 2003).
1.1.3. Genetic and molecular alterations characteristic of malignant glioma
In the past five years, studies conducting comprehensive genomic and protein
expression profiling of adult and pediatric malignant glioma revealed differences in gene
copy number alterations and transcriptional profiles (Parsons et al., 2008; Paugh et al.,
2010a; TCGA, 2008) (Table 1-1). These studies revealed that the function of several
tumor suppressor pathways such as P53 and retinoblastoma (Rb) is commonly mutated or
deleted in both adult and pediatric gliomas (Newcomb et al., 2000; Pollack et al., 2001;
Suri et al., 2009; TCGA, 2008). Alteration of multiple receptor tyrosine kinases (RTKs)
signaling pathways is another frequent genetic finding in malignant gliomas (Parsons et
al., 2008; Paugh et al., 2010a; Stommel et al., 2007; TCGA, 2008). RTKs are a family of
cell surface receptors that can be activated by extracellular ligands. Upon activation,
RTKs phosphorylate tyrosine residues on several target proteins resulting in their
activation (Fan and Weiss, 2010; Robinson et al., 2000). The signal initiated by RTKs is
then transduced and amplified through intracellular downstream pro-survival signaling
cascades, such as the phosphatidyl inositol 3-kinase/Akt (PI3K/Akt) pathway or the
mitogen-activated protein kinase (MAPK) pathway, leading to increased tumor cell
survival, migration, and invasiveness (Fan and Weiss, 2010; Ren et al., 2007) (Figure
1-1). RTKs shown to play a role in the development, progression, or therapeutic
resistance of malignant glioma include the epidermal growth factor receptor (EGFR),
platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor
receptor (VEGFR) (Ayuso-Sacido et al., 2010; Paugh et al., 2010a; Raymond et al., 2000;
Squatrito and Holland, 2011).
About half of adult glioma cases exhibit mutation or amplification in EGFR
(TCGA, 2008). Deletion or mutation of the phosphate and tensin homolog tumor
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Table 1-1.
Summary for important genetic alteration in adult and pediatric
malignant glioma
Gene

Alteration in adult glioma
patients

Alteration in pediatric glioma
patients

EGFR

Amplification (25%) (Parsons et
al., 2008; TCGA, 2008)
Mutation (3.3%) (TCGA, 2008)
Mutation and amplification
(17.5%) (TCGA, 2008)
Amplification (13%)(TCGA,
2008)
Amplification (4%)(TCGA,
2008)

Amplification (rare) (0-7%)
(Bredel et al., 1999; Paugh et al.,
2010a; Pollack et al., 2006; Sung
et al., 2000; Suri et al., 2009)

PDGFRA
c-MET

PTEN
P53 Pathway

RB Pathway

Mutation, homozygous deletion
(36%) (Parsons et al., 2008;
TCGA, 2008)
TP53: Mutation, homozygous
deletion (35%) (TCGA, 2008)
Genes that regulate p53 stability:
MDM2, amplified in 14%,
MDM4, amplified in 7%
CDKN2A, homozygous deletion
or mutation in 52%
Collectively, this pathway is
targeted in 87% of cases (TCGA,
2008)
RB1: Mutation, homozygous
deletion (11%)(TCGA, 2008)
Genes that regulate Rb activity:
CDKN2A, deletion or mutation
in 52%
CDKN2B, deletion in 47%
Collectively, this pathway is
altered in 78% of cases
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Amplification (14%) (Paugh et
al., 2010a)
Amplification (rare in GBM 3%
but more common in diffuse
intrinsic pontine glioma 26%)
(Paugh et al., 2010a)
Deletion (rare) (0-5%) (Pollack et
al., 2006; Suri et al., 2009)
Mutation (34%)(Pollack et al.,
2001)

CDKN2A, homozygous deletion
(10%) (Newcomb et al., 2000)

Figure 1-1.

Schematic presentation of signaling pathways targeted by molecular therapies in malignant glioma

The diagram illustrates pathways that are activated upon RTK activation. PDGFR, EGFR, and VEGFR activation share
common intracellular effectors. Arrowheads indicate signal transduction while a blunted end indicates inhibition of a target.
Source: Adapted by permission from Springer. Mercer RW et al. (2009) Targeted Therapies for Malignant Glioma Progress
and Potential. BioDrugs 23:25-35.
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suppressor gene (PTEN), the major inhibitor of PI3K/Akt signaling pathway is found in
36% of these tumors (TCGA, 2008). In contrast, pediatric glioma cases rarely exhibit
EGFR gene amplification or PTEN gene deletion or mutation (0-5%) (Paugh et al.,
2010a; Pollack et al., 2006; Sung et al., 2000; Suri et al., 2009). Despite the low
frequency of EGFR amplifications in childhood glioma, EGFR protein overexpression is
observed in up to 85% of the cases (Bredel et al., 1999; Gilbertson et al., 2003; Pollack et
al., 2006; Thorarinsdottir et al., 2008).
In pediatric gliomas, platelet-derived growth factor alpha (PDGFRA) is the
predominant target of focal amplification (Paugh et al., 2010a). The extent of PDGFRα
activation, measured by the receptor phosphorylation of several tyrosine residues, is
significantly associated with the malignant histology of childhood gliomas
(Thorarinsdottir et al., 2008). Other receptor tyrosine kinases, such as c-MET, may be
altered in adult and pediatric gliomas (Paugh et al., 2010a; TCGA, 2008). The different
frequencies of genetic alterations between adult and pediatric gliomas reflects the
complexity and heterogeneity of these tumors and indicates the need for molecularly
targeted therapies directed towards the aberrant signaling pathways in individual tumors.
The activation status of critical glioma survival pathways, such as PI3K/Akt, is
determined by redundant inputs from multiple receptor tyrosine kinases (RTKs) such as
EGFR, PDGFR, and c-MET. The signals provided by these RTKs can be either used
simultaneously or sequentially by glioma cells to maintain an active downstream
PI3K/Akt signaling and thus inhibiting PI3K/Akt signaling may require targeting
multiple RTKs (Stommel et al., 2007).
1.1.4. Current approaches for treatment of malignant glioma
The prognosis and clinical outcome for AA patients is better than those diagnosed
with GBM (Broniscer et al., 2005; Finlay et al., 1995; Rutten et al., 1981). Despite
aggressive treatment modalities, including surgical resection, radiation, and
chemotherapy, the median overall survival of patients with newly diagnosed GBM is less
than 4 years for children and 1.5 years for adults (Minniti et al., 2008; Song et al., 2010;
Stupp et al., 2005). The infiltrative nature of malignant glioma allows these tumors to
invade and metastasize through the brain parenchyma. Ultimately, this invasive
propensity leads to failure of surgical resection to achieve complete tumor removal
(Amberger-Murphy, 2003; Giese et al., 2003).
For adult patients newly diagnosed with malignant glioma, the standard treatment
regimen for adults is radiotherapy (2 Gray per day 5 days per week for 6 weeks, for a
total of 60 Gray), plus continuous daily administration of temozolomide, a DNA
alkylating agent. This is followed by six cycles of temozolomide (150 to 200 mg per
square meter for 5 days during each 28-day cycle). This regimen modestly improved the
median survival of GBM patients to 14.6 months as compared to 12.1 months with
radiotherapy alone (Stupp et al., 2007; Stupp et al., 2005).
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Given the highly vascular nature of malignant glioma, angiogenesis inhibitors,
especially those targeting VEGF signaling, have been used alone or in combination with
chemotherapeutic agents for the treatment of adult recurrent glioblastoma. A multi-center
phase II study reported a notable improvement of the 6-month progression-free survival
in patients with recurrent GBM treated with bevacizumab, a VEGF monoclonal antibody,
when compared to historical controls treated with irinotecan alone (Friedman et al.,
2009). The impressive results reported in this study led to the accelerated US Food and
Drug Administration approval of bevacizumab for treatment of adult patients with
recurrent glioblastoma.
In contrast to their adult counterparts, pediatric glioma patients showed poor
response to the standard of care of the adult population. The administration of
temozolomide after radiation therapy failed to improve the poor prognosis of children
with malignant glioma (Broniscer and Gajjar, 2004; Broniscer et al., 2005). Further,
disappointing results were reported in trials using bevacizumab and irinotecan in
treatment of children with recurrent malignant glioma (Gururangan et al., 2010). For
pediatric glioma patients, maximum safe surgical resection and radiation therapy is the
mainstay of treatment. The striking differences between the pediatric and adult
populations in their response to several therapeutic regimens, despite their histological
similarities, support the use of regimens that target specific pathways altered in each
tumor (Broniscer and Gajjar, 2004).
1.1.5. Emerging treatments for malignant glioma
The advances in our understanding of the genetic alterations of these tumors allow
for the identification of molecular targets that are important for tumor survival and
progression. Aberrant signaling through RTKs such as EGFR, PDGFRα, and VEGFR
results in activation of downstream effectors that promote cellular proliferation, survival,
invasiveness, and inhibits apoptosis of glioma cells (Ayuso-Sacido et al., 2010; Hatanpaa
et al., 2010; Sharma et al., 2011). Thus, inhibiting these pathways represent a reasonable
therapeutic strategy in attempts to inhibit tumor growth.
1.1.5.1. Inhibitors of EGFR pathway
Alteration of the EGFR signaling pathway is a common feature in adult glioma in
the form of gene amplification or mutation (TCGA, 2008), and in pediatric glioma in the
form of protein overexpression (Bredel et al., 1999; Gilbertson et al., 2003; Pollack et al.,
2006; Thorarinsdottir et al., 2008). These findings make EGFR an attractive target in the
management of malignant glioma.
Gefitinib (Iressa, Astra Zeneca) and erlotinib (Tarceva, OSI Pharmaceuticals) are
both quinazolin-4-amine derivatives with specific and potent inhibitory activity against
EGFR. Both gefitinib and erlotinib competitively bind to the cytoplasmic ATP-binding
domain of EGFR and inhibits its tyrosine kinase activity. This prevents EGFR
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phosphorylation and interrupts its downstream signaling cascade (Raymond et al., 2000).
In vitro, erlotinib was shown to suppress anchorage-independent growth and induce
apoptosis in glioma cell lines (Halatsch et al., 2004).Only erlotinib, not gefitinib, can
inhibit the most common type of EGFR mutation, EGFRvIII, which lacks a portion of the
extracellular ligand binding domain rendering EGFR constitutively active (Heimberger et
al., 2002; Peereboom et al., 2010).
EGFR inhibitors were shown to reduce tumor growth and prolong survival in
subcutaneous xenograft models of high-grade glioma (Ciardiello et al., 2001; Heimberger
et al., 2002). However, neither gefitinib nor erlotinib showed clinical benefit in
improving the overall survival in adult or pediatric patients with high-grade glioma
(Geoerger et al., 2011; Peereboom et al., 2010; Prados et al., 2009; Raizer et al., 2010b;
Reardon et al., 2006; Rich et al., 2004; van den Bent et al., 2009a).This might be
explained by previous reports indicating that targeting EGFR only is insufficient for
inhibiting downstream PI3K/Akt signaling and that more effective therapy may require
targeting of multiple RTKs (Stommel et al., 2007).
1.1.5.2. Inhibitors of PDGFR pathway
The two isoforms PDGF-A and B homo or hetero-dimerize, bind to, and induce the
activation of PDGFR α or β. Activated PDGFRα or PDGFRβ then activate PI3K/Akt and
MAPK pathways (Liu et al., 2011). PDGFRα or β are commonly overexpressed in
glioma (Guha et al., 1995; Liang et al., 2008; Mauro et al., 1991; Nister et al., 1991;
Thorarinsdottir et al., 2008) and are thought to play an important role in tumor
invasiveness and angiogenesis (Pietras et al., 2003; Thorarinsdottir et al., 2008).
Imatinib (Gleevec, Novartis) is an RTK inhibitor that targets Bcr-Abl and c-kit.
Imatinib also inhibits PDGFR activation though at concentrations higher than that
required for Bcr-Abl and c-kit inhibition (Mahboobi et al., 2008). Imatinib showed
promising results in xenografts derived from the human glioma cell lines U343 and
U87-MG. In these studies, oral administration of imatinib prolonged the survival of
subcutaneous xenograft mouse models with PDGFR-expressing tumors (Kilic et al.,
2000). The excitement resulting from these preclinical data faded when disappointing
results were reported in phase II studies in recurrent glioma patients. The reports showed
that imatinib failed to prolong the 6 months progression free survival of recurrent glioma
patients (Raymond et al., 2008; Wen et al., 2006). Furthermore, a Phase III study
comparing the efficacy of the combination of imatinib and adjuvant chemotherapy versus
chemotherapy alone in heavily pretreated malignant glioma patients showed similar
median progression free survival in both treatment arms which indicates limited clinical
benefit of the combination (Dresemann et al., 2010).
Reports showing limited CNS penetration of imatinib, together with its low potency
and lack of specificity for PDGFR inhibition, raised some questions on whether imatinib
is a suitable drug for treatment of malignant glioma and suggested the need for more
specific and potent PDGFR inhibitors with better CNS penetration profiles (Mahboobi et

7

al., 2008; Neville et al., 2004). Fortunately, specific inhibitors of the PDGFR pathway,
such as crenolanib, are available (AROG Pharmaceuticals, LLC). Crenolanib is an orally
bioavailable, highly specific, and potent PDGFR inhibitor that targets both α and β
receptor types (Lewis et al., 2009). Crenolanib is more than 100-fold more selective
towards PDGFR than other kinases, such as c-KIT, VEGFR-2, and EGFR (Lewis et al.,
2009). Crenolanib (50 mg/kg twice daily) resulted in 47% inhibition of tumor growth in
U87-MG human glioma subcutaneous xenografts (AROG Pharmaceuticals, LLC,
Investigator’s Brochure Crenolanib Besylate March 2011). To our knowledge, crenolanib
CNS penetration has not been reported to date. Currently, crenolanib is undergoing phase
I trials in children and phase II trials in adult patients with malignant glioma.
1.1.5.3. Inhibitors of VEGFR pathway
The development of neovasculature, angiogenesis, is an important process for the
growth and invasiveness of malignant glioma. The high angiogenic capacity of glioma is
primarily mediated by VEGF although other proangiogenic factors, such as PDGF and
fibroblast growth factor (FGF), can also contribute (Guo et al., 2003; Plate et al., 1992;
Schmidt et al., 1999). VEGF binds to its receptors, mainly VEGFR-2, on tumor vessels
resulting in increased vascular permeability and enhanced endothelial cell proliferation,
survival, and migration. Distinct structural and functional abnormalities differentiate the
newly formed tumor vessels from normal vessels (Plate et al., 1992). Tumor endothelial
cells are tortuous with large fenestrations, abnormal basement membrane, and reduced
pericyte coverage (Jain, 2005; Morikawa et al., 2002). Thus, despite the increased
microvessel density in glioma, the blood flow in these vessels is heterogeneous and
sluggish which leads to hypoxia, acidosis, necrosis, and elevated tumor interstitial
pressure (Fukumura and Jain, 2007; Hanahan and Folkman, 1996; Jain, 2001; 2005).
Given the highly angiogenic nature of malignant glioma, targeting angiogenic
signaling pathways was shown to be a reasonable therapeutic strategy for these tumors
(Batchelor et al., 2007; Brastianos and Batchelor, 2010; Kamoun et al., 2009). Inhibitors
of the VEGF signaling pathway are the most clinically developed of the anti-angiogenic
therapies. Two strategies to target VEGF signaling pathway are currently being tested;
the first is targeting the ligand, VEGF, using VEGF monoclonal antibodies such as
bevacizumab (Avastin, Genentech-Roche), and the second is targeting the VEGF receptor
expressed on capillary endothelial cells, VEGFR2 (McMahon, 2000; Reardon et al.,
2011).
Recent findings showed that bevacizumab in combination with irinotecan improved
the 6 months progression free survival of patients with recurrent GBM to 46% compared
to 21% with historical controls, indicating potential benefit of anti-angiogenic agents
(Vredenburgh et al., 2007). More than half the patients on this trial had at least a partial
radiological response measured by the extent of tumor enhancement on T1-weighted
MRI scans (Vredenburgh et al., 2007).
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Several small molecules targeting VEGFR have been developed such as cediranib
(Recentin, AstraZeneca). Cediranib, a pan inhibitor of VEGFR, successfully increased
survival and led to vascular normalization and edema alleviation in orthotopic glioma
mouse models despite continuous tumor enlargement in the cediranib-treated group
(Kamoun et al., 2009). A similar, though less pronounced effect, was observed upon
treating these mice with dexamethasone. These findings suggest that the effect observed
with cediranib treatment is more likely to be associated with edema alleviation than with
direct anti-tumor effect (Kamoun et al., 2009). In phase II trials for adult patients with
recurrent glioblastoma, cediranib showed improved 6 months progression free survival
(26%), though overall survival was similar to historical controls. Tumor vascular
normalization was rapidly reversed upon interruption of the cediranib regimen (Batchelor
et al., 2007).
Ultimately, VEGFR pathway inhibitors produced only modest improvement in the
overall survival in patients with malignant glioma. This raised the question of whether the
observed improvement in radiological response and progression free survival is due to a
genuine anti-tumor effect or merely a result of reduced vascular permeability that limits
tumor enhancement on T1-weighted MRI. Thus, some oncologists advocate
reconsidering the anti-edematous effect of bevacizumab as an expensive steroid-like
effect (van den Bent et al., 2009b; Wick et al., 2010).
1.1.6. Challenges facing molecularly targeted therapies in malignant glioma
In general, results from molecularly targeted agents in treatment of malignant
glioma patients have been disappointing despite some encouraging in vitro and
preclinical data. No major survival advantage has been observed with any of these agents
in phase II or III trials (Batchelor et al., 2007; Dresemann et al., 2010; Peereboom et al.,
2010; Raizer et al., 2010b; Rich et al., 2004). The failure of these agents may be
explained by several resistance mechanisms. These include coactivation of multiple
receptor tyrosine kinases that provide redundant signals to maintain active downstream
signaling. Coactivation of three or more RTKs that include EGFR, PDGFRα, and c-MET
was demonstrated in 19/20 glioma cell lines (Stommel et al., 2007). Inhibition of
downstream PI3K signaling could only be accomplished when all activated receptors
were targeted while inhibiting single RTK did not affect downstream signaling (Stommel
et al., 2007; Thaker and Pollack, 2009). Thus, understanding the pathways activated in
individual patients and simultaneously targeting multiple components of the PI3K
pathway using combination regimens may provide clinical benefit for patients with
malignant glioma (Mercer et al., 2009; Stommel et al., 2007; Thaker and Pollack, 2009).
Further, resistance of malignant glioma to some tyrosine kinase inhibitors can be
explained by the deletion of key tumor suppressor proteins such as PTEN, a genetic
alteration almost exclusive to adult glioma patients, leading to constitutive receptorindependent activation of the PI3K/Akt pathway (Mellinghoff et al., 2005). Recently, the
genetic complexity of these tumors was recently highlighted in microarray studies that
identified several molecular subclasses of GBM where each of these subclasses responds
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differently to treatment indicating that malignant gliomas are more complex than being
just a single disease type (Phillips et al., 2006; Verhaak et al., 2010).
The effectiveness of molecularly targeted therapies depends upon achieving
sufficient concentrations of these agents in the tumor for adequate duration. To induce a
therapeutic effect, the plasma protein-unbound portion of these agents should access the
relevant target site within the tumor. The concentration of unbound drug achieved within
the tumor depends on several factors, which include absorption, distribution, metabolism,
and elimination (i.e., pharmacokinetics) of the drug, the toxicity associated with its
administration, the extent of plasma protein binding, and the ability of the drug to cross
the blood-brain barrier (BBB). The BBB limits tumor penetration of these agents and thus
may provide plausible explanation for the lack of efficacy of drugs with limited CNS and
tumor penetration (Tredan et al., 2007; Westerhout et al., 2011). Moreover, the
distribution of anti-cancer drug throughout the tumor is non-uniform (Jain, 2005).
Uniform distribution of effective concentration of the anti-cancer drug throughout the
tumor may allow the anti-cancer agent to encounter more tumor cells and thus improve
its anti-tumor activity.
1.2. BARRIERS AGAINST ANTI-CANCER DRUG CNS PENETRATION
The brain is protected by a dynamic barrier that maintains the stability of the brain
function by separating the brain from the systemic circulation and hence the name bloodbrain barrier (BBB) (Figure 1-2) (Rubin and Staddon, 1999). The BBB plays an
important role in protecting the sanctuary of the brain and its normal development from
circulating toxins and harmful chemicals. As a result, the brain will have limited
exposure to drugs intended to treat neurological diseases and brain tumors (McCarty,
2005; Rubin and Staddon, 1999).
The BBB is composed of capillary endothelial cells which are supported by
pericytes, astrocytes, and microglial cells (McCarty, 2005). These endothelial cells are
connected to each other by a number of integral membrane proteins such as occludins,
caludins, and ZO 1-3, forming tight junctions that block the paracellular (between cell)
transport of xenobiotics including anti-cancer drugs (Figure 1-2) (Kniesel and Wolburg,
2000; Wolburg and Lippoldt, 2002). To overcome this paracellular impermeability, drugs
have to pass through the endothelial cells (i.e., trans-cellular route) to reach the brain
(Pardridge, 1999; Terasaki and Ohtsuki, 2005).
Some drugs with high lipophilicity, low polar surface area, and low molecular
weight can pass through the transcellular route via passive diffusion. However, several
transport proteins on the endothelial cells can limit the brain penetration of these
molecules despite their favorable physicochemical properties (Eros et al., 2002; Mahar
Doan et al., 2002; McCarty, 2005; Pardridge, 1998; Rubin and Staddon, 1999). Members
of the ATP-binding cassette (ABC) transporter family are efflux pumps expressed on the
endothelial cells. These pumps transport molecules across the BBB into the blood against
their concentration gradient by utilizing energy from ATP hydrolysis (PL and GM, 2003;
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Figure 1-2.
up the BBB

Schematic representation of the capillary endothelial cells that build

A. Cross-section through a brain capillary.
B. Longitudinal section across the wall of the capillary, with the tight junctions that
separate the membranes into the luminal (i.e. apical) and abluminal (i.e. basolateral)
sides.
Source: Reprinted by permission from the American Physiological Society. Hagenbuch B
et al. (2002) Transport of xenobiotics across the blood-brain barrier. News in
Physiological Sciences 17:231-234.
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Terasaki and Hosoya, 1999). ABC transporters known to restrict CNS distribution of
anti-cancer agents include ABCB1 [MDR1; P-glycoprotein (P-gp)], ABCC1 [multidrug
resistance-associated protein 1 (MRP1)], ABCC4 (multidrug resistance-associated
protein 4 (MRP4), and ABCG2 [breast cancer resistance protein (BCRP)] (PL and GM,
2003; Terasaki and Hosoya, 1999).
Another important family of transporters expressed on endothelial cells is the
solute carrier (SLC) family of transporters (Koepsell and Endou, 2004). In contrast to the
ABC transporter family, members of the SLC family do not require ATP for their
function (Degorter et al., 2011; Hediger et al., 2004). SLC transporters mediate the
movement of their substrates via several mechanisms, including carrier-mediated (i.e.
facilitated diffusion), ion coupling, and ion exchange mechanisms (Hediger et al., 2004).
They are primarily involved in the influx of drugs and endogenous compounds to the
brain. Previous reports showed CNS expression of several SLC family members where
they play an important role in drug transport across the BBB (Angeletti et al., 1997; Gao
et al., 2000; Gao et al., 1999; Lin et al., 2010; Noe et al., 1997; Roberts et al., 2008;
Urquhart and Kim, 2009; WM, 2003).
Another barrier involved in anti-cancer drug CNS distribution is the bloodcerebrospinal fluid barrier (BCSFB) (Johanson et al., 2005). This barrier is composed
mainly of the choroid plexus, a layer of polarized epithelial cells lining the ventricles
(Redzic and Segal, 2004). The choroid plexus is comprised of two layers, an inner layer
of endothelial cells and an outer layer of ependymal cells (Redzic and Segal, 2004).
While endothelial cells of the BCSFB are fenestrated, tight junctions are present between
the outer ependymal cells (Redzic and Segal, 2004; Zheng et al., 2003). These tight
junctions restrict the paracellular transport across the choroid plexus (Redzic and Segal,
2004; Zheng et al., 2003). Thus, to enter the CSF, molecules have to cross the fenestrated
capillary wall and penetrate the ependymal cells of the choroid plexus. Similar to the
BBB, drug trafficking across the BCSFB is also controlled by efflux and uptake
transporters (Kusuhara and Sugiyama, 2004).
Many factors are involved in the transport of drugs across the brain barrier membranes.
Localization of efflux and uptake transporters either on the apical side of the BBB (facing
the blood) or the basolateral side (facing the brain) will affect the disposition of their
substrates in the brain extracellular fluid (ECF) (Figure 1-3) (Shen et al., 2009;
Westerhout et al., 2011; Zhuang et al., 2006). Likewise, the localization of these
transporters on the apical side of the choroid plexus epithelia (facing the CSF) or the
basal side (facing the blood) will impact the translocation of their substrates in the CSF
(de Lange, 2004; Shen et al., 2009; Wijnholds et al., 2000; Zhuang et al., 2006). In the
following section, the localization of efflux transporters namely P-glycoprotein (P-gp,
ABCB1), breast cancer resistance protein (BCRP, ABCG2), and multidrug resistanceassociated protein 4 (MRP4) and their impact on the disposition of their substrates within
different CNS compartments will be discussed. Furthermore, the expression of solute
carrier transporters organic anion-transporting polypeptide 1A2 (OATP1A2), organic
anion transporter 3 (Oat3), and the organic cation transporter 2 (OCT2) will be reviewed.
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Figure 1-3.

Schematic representation of the BBB

Brain endothelial cells are surrounded by a basal membrane, astrocyte foot processes,
and supportive pericytes. Tight junctions in brain capillary endothelial cells prevent
paracellular transport through the BBB. Transcellular diffusion through the BBB is
affected by efflux and uptake transporters illustrated in the lower portion of the figure.
P-gp, BCRP, MRP1, MRP4, and OCT2 are localized on the apical border while Oat3
is expressed predominantly on the basolateral membrane. Oatp2 is expressed at both
apical and basolateral borders.
Source: Adapted by permission from the American Association for Cancer Research.
Deeken J et al. (2007) The Blood-Brain Barrier and Cancer: Transporters, Treatment,
and Trojan Horses. Clin Cancer Res 13:1663-1674.
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1.2.1. ATP-Binding Cassette family
1.2.1.1. P-glycoprotein (P-gp/ABCB1)
P-gp is the most widely studied of all efflux drug transporters. In humans, P-gp is
encoded by the MDR1 gene while two genes, Mdr1a and Mdr1b, encode P-gp in the
rodent brain (Bendayan et al., 2002; Gottesman, 1993; Schinkel et al., 1996). P-gp is
highly expressed on the luminal side of the capillary endothelial cells of the BBB in
humans, mice, rats, and dogs (Beaulieu et al., 1997; Cordon-Cardo et al., 1989; Hegmann
et al., 1992; Thiebaut et al., 1989) (Figure 1-3). It is widely accepted that P-gp plays an
important role in limiting the accumulation of its substrates in the brain ECF and thus
conferring resistance to these agents (Nobmann et al., 2001; Pardridge, 2005; Schinkel et
al., 1995).
Expression of P-gp at the ependymal cells of the choroid plexus has been
established in humans, mice, and rats by several groups (Daood et al., 2008; Rao et al.,
1999a; b; Zhuang et al., 2006). However, the exact localization of P-gp to either side of
the choroid plexus is not clear yet. In humans, P-gp is thought to localize apically at the
BBB (Beaulieu et al., 1997; Daood et al., 2008; Rao et al., 1999a). In rodents, P-gp was
found to exhibit a granular expression pattern throughout the cytoplasm with enhanced
expression on the apical side of the choroid plexus (Figure 1-4) (Zhuang et al., 2006).
Given its localization, P-gp can play an important role in active transport of its substrates
into the ventricular CSF. This will increase the concentration of P-gp substrates in the
CSF. Using noninvasive single-photon-emission computed tomography, Rao et al
showed that CSF levels of the P-gp substrate 99mTc-sestamibi is 100-fold more than that
in blood (Rao et al., 1999b). Our group showed that accumulation of topotecan, a P-gp
substrate, was significantly higher in the CSF of wild-type mice compared to mice
lacking P-gp, i.e. Mdr1a/b-/- (Shen et al., 2009). Collectively, these data indicate an
important role for P-gp in the blood to CSF transport of its substrates.
Important insights to the function of P-gp were obtained from experiments
conducted with mouse models lacking either one or both of the P-gp encoding genes, i.e.
Mdr1a-/- and Mdr1a/1b-/- mice (Schinkel et al., 1994; Schinkel et al., 1995; Wijnholds et
al., 2000). These models were used to demonstrate the role of P-gp in drug disposition in
the ECF or the CSF. Schinkel et al showed striking 12-fold higher brain concentrations of
vinblastine, a P-gp substrate, in ECF of Mdr1a-/- mice compared to wild-type mice
(Schinkel et al., 1994). These models played an important role in studies that evaluate the
role of P-gp in restricting CNS penetration of several molecularly targeted agents that are
currently being tested for treatment of high-grade glioma (Agarwal et al., 2010; Marchetti
et al., 2008; Poller et al., 2011).
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Figure 1-4.

Schematic representation of the BCSFB

Fenestrated capillaries in the choroid plexus permit free transport of molecules. However,
tight junctions on the choroid plexus epithelial cells limit paracellular transport.
The CSF-facing surface of the epithelial cells is called the apical border while that facing
the blood side is called the basolateral border. The figure illustrates the current view of
the localization of drug transporters at the choroid plexus epithelial cells. P-gp is
predominantly located at the apical side and seems to transport into its substrates into the
CSF. BCRP exhibits similar localization to P-gp. MRP1 and MRP4 are localized on the
basolateral border and they are thought to mediate transport out of the CSF into the
blood. Uptake transporters such Oat3 is predominantly expressed on the basolateral
border. The rodent orthologues Oatp1 and Oatp2 corresponding to human OATP1A2, are
expressed at the apical membrane of the choroid plexus in case of Oatp1 or at both apical
and basolateral membranes.
Source: Adapted by permission from the American Association for Cancer Research.
Deeken J et al. (2007) The Blood-Brain Barrier and Cancer: Transporters, Treatment,
and Trojan Horses. Clin Cancer Res 13:1663-1674.
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1.2.1.2. Multi-drug resistance associated proteins (MRPs/ABCC)
The ABCC subfamily of ABC transporters consists of 12 members, nine of them
(MRP1-9) have been implicated in conferring drug resistance. Of these nine members,
MRP1 and MRP4 are the most relevant to anti-cancer drugs used in treatment of brain
tumors.
MRP1 is expressed on the apical side of the capillary endothelial cells forming the
BBB (Figure 1-3). According to this orientation, MRP1 can limit the penetration of their
substrates to brain ECF. Mrp1-/- mouse models show higher brain accumulation and
enhanced sensitivity towards MRP1 substrates such as the topoisomerase II interacting
agent, etoposide, compared to their wild type counterparts (Lorico et al., 1997; Wijnholds
et al., 1997).
On the choroid plexus, Mrp1 is expressed on the basolateral side of the
ependymal cells. This localization, in contrast to P-gp localization, allows the efflux of
drugs from the CSF into the blood (Figure 1-4). The role of MRP1 in CSF to blood
transport was confirmed by studies showing 10-fold higher etoposide accumulation in the
CSF of Mrp1-/- mice (Wijnholds et al., 2000). Given its role on the BBB and the BCSFB,
Mrp1 can serve as an important detoxification system of the whole brain (de Lange,
2004).
Similar to Mrp1, MRP4 is expressed on the apical membrane of the endothelial
cells of the BBB (Figure 1-3) and on the basolateral membrane of the choroid plexus
(Figure 1-4) (Huai-Yun et al., 1998; Leggas et al., 2004a; Nies et al., 2004; Roberts et
al., 2008; Zhang et al., 2000). Leggas et al showed increased topotecan brain penetration
in Mrp4-/- mice compared to wild-type mice indicating a potential role for MRP4 in
restricting topotecan brain ECF accumulation (Leggas et al., 2004a). Further, MRP4 was
shown to reduce the intracellular accumulation of the tyrosine kinase inhibitor imatinib in
MRP4 expressing Saos-2 cells (Hu et al., 2008). This suggests that MRP4 can play an
important role in disposition of several chemotherapeutic and molecularly targeted
agents. Further investigation is necessary to elucidate the role of MRP4 in brain transport
of other molecularly targeted agents.
1.2.1.3. Breast cancer resistance protein (BCRP/ABCG2)
Another member of the ABC transporter family was first identified in a breast
cancer cell line MCF-7/AdrVp and hence named breast cancer resistance protein (BCRP)
(Doyle et al., 1998). Additional studies showed that BCRP is expressed on the apical side
of the capillary endothelial cells in humans, rats, and mice brains where it has been
implicated in brain to blood transport of its substrates (Figure 1-3) (Cooray et al., 2002;
Hori et al., 2004). On the human choroid plexus, BCRP expression has not been
extensively studied. However, studies from mouse and rat brain showed apical
localization on the choroid plexus (Figure 1-4) (Zhuang et al., 2006). This P-gp-like
localization, suggests that BCRP limits the penetration of its substrates to brain ECF and
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transports these agents across the BBB into the systemic circulation. Similar to P-gp
function on the BCSFB, BCRP was shown to transport its substrates into the CSF. In
Bcrp1-/- mice, BCRP substrates showed lower CSF accumulation compared to wild-type
mice (Shen et al., 2009; Zhuang et al., 2006).
BCRP and P-gp show a considerable overlap in their substrate specificity. Recent
reports suggested that BCRP and P-gp cooperate to limit CNS penetration of their dual
substrates (Agarwal et al., 2010; de Vries et al., 2007; Shen et al., 2009). Several tyrosine
kinase inhibitors were shown to be dual substrates for P-gp and BCRP. For example, in
Bcrp1-/- mice or Mdr1a/b -/- mice, little to no difference was observed in brain penetration
of several tyrosine kinases compared to wild-type mice. However, in Mdr1a/b-/-/Bcrp1-/mice that lack both transporters, brain penetration of these agents are significantly
elevated (Agarwal et al., 2011c; Chen et al., 2009; Polli et al., 2008). In some cases, drug
levels in the brain are even higher than that in the systemic circulation which suggests a
potential role of influx mechanisms responsible for the blood to brain transport of these
molecules across the BBB (Agarwal et al., 2010; Kodaira et al., 2010; Kusuhara and
Sugiyama, 2005).
1.2.1.4. Pharmacological inhibition of efflux transporters
Given the important effect of P-gp and BCRP on CNS anti-cancer drug
disposition, several modulators of these transporters were developed in attempts to
increase the delivery of anti-cancer drugs to therapeutically resistant tumors located
behind the BBB. First generation inhibitors of P-gp were drugs known to be P-gp
substrates such as verapamil and cyclosporin A. The use of these agents in combination
with anti-cancer agents was associated with significant drug-related side effects in
patients (Sikic et al., 1997). The increased toxicity can be explained by first, the lack of
specificity and poor binding affinity of these agents to P-gp. Thus, transport inhibition
can only be achieved at high exposures that can lead to toxicity. Second, verapamil and
cyclosporin A are inhibitors of cytochrome P450 enzymes, which are commonly
responsible for the metabolism of anti-cancer agents. Thus, combining non-specific P-gp
modulator with anti-cancer agents resulted in lower systemic clearance and consequently
increased toxicity of anti-cancer agents.
Second generation modulators, such as the cyclosporin A analog, PSC833, are
more specific and potent P-gp inhibitors. However, PSC833 also inhibited CYP3A
enzymes. Therefore, third-generation inhibitors, such as elacridar (GF120918), and
tariquidar (XR9576) (Hyafil et al., 1993; Roe et al., 1999), were developed to mainly
modulate the transport function with little impact on liver metabolizing enzymes, which
is reflected via better safety profiles in patients (Hyafil et al., 1993; Kruijtzer et al., 2002).
Tariquidar is considered a specific P-gp inhibitor (Roe et al., 1999) while elacridar also
inhibits human BCRP and mouse Bcrp1 (Hyafil et al., 1993; Maliepaard et al., 2001). To
our knowledge, the efficacy of second or third generation transporter modulators in
combination with molecularly targeted agents has not been assessed in patients with highgrade glioma.
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1.2.2. Solute carrier transporters
1.2.2.1. Organic anion transporter-3 (OAT3)
Oat3 is predominantly expressed on the basolateral side of mouse brain
endothelial cells (Figure 1-3) (Ohtsuki et al., 2004). In rat brain, Oat3 is predominantly
expressed on the basolateral side of the capillary endothelial cells with less expression on
the luminal side (Kikuchi et al., 2003). This unique expression pattern enables Oat3 to
mediate the transport of its substrates into or out of the brain. Reports studying CNS
disposition of the typical Oat3 substrate p-aminohippurate (PAH) in rats showed both
efflux and uptake processes of PAH to occur. However, the magnitude of PAH efflux
was found to be 4 times higher than its uptake (Kusuhara et al., 1999; Kusuhara and
Sugiyama, 2005). This suggests that Oat3 will have a net effect of extruding its substrates
from the brain (Kusuhara and Sugiyama, 2005).
On the choroid plexus, Oat3 is expressed on the basolateral border of the
ependymal cells (Figure 1-4). Oat3 seems to mediate the transport of its substrates in an
opposite direction to that of P-gp and BCRP (i.e., from the CSF to the blood) (Kikuchi et
al., 2003; Sykes et al., 2004).
Oat3 has been shown to transport several drugs with antitumor activity such as
6-mercaptopurine and 6-thioguanine (Mori et al., 2004). However, further studies are
warranted to assess the contribution of Oat3 to the disposition of anti-cancer agents used
to treat glioma.
1.2.2.2. Organic cation transporter-2 (OCT2)
OCT2 is primarily expressed at the basolateral membrane of renal proximal
tubules (Karbach et al., 2000; Motohashi et al., 2002) but it has also been detected in
human neurons (Slitt et al., 2002). OCT2 is expressed on the apical side of human brain
endothelial cells similar to the rodent orthologues, Oct1 and Oct2 (Figure 1-3) (Lin et al.,
2010). Typical OCT2 substrates are organic cations or weak bases (Nies et al., 2011).
However, uncharged compounds such as cimetidine and non-ionizable compounds such
as corticosteroids were shown to interact with OCT2 in a pH-dependent manner (Barendt
and Wright, 2002). Further, OCT2 was shown to interact with organic anions such as
probenecid (Hsyu et al., 1988).This substrate poly-specificity can be attributed to the
existence of distinct hydrophobic and cationic sides on OCT2 (Rennick, 1981).
On the BBB, OCT2 mediates the facilitated diffusion of several endogenous
substrates and drugs. For example, the administration of the OCT2 inhibitor, amantadine,
reduced the uptake of the OCT2 substrate, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
in brain ECF (Lin et al., 2010). On the BCSFB level, the role of OCT2 is not clear yet.
OCT2 mRNA expression could not be detected on the rat choroid plexus epithelium
which suggests minimal, if any, contribution of OCT2 to drug disposition across the

18

BCSFB (Choudhuri et al., 2003). Further studies are needed to understand the role of
OCT2 in CNS disposition of several anti-cancer agents. The availability of Oct2-/- murine
models will allow better understanding of the role of this transporter in carrier-mediated
transport of several anti-cancer agents (Jonker et al., 2003).
1.2.2.3. Organic anion transporter polypeptide 1A2 (OATP1A2)
OATP1A2 is a member of the SLCO family of influx transporters that regulates
the cellular level of several endogenous and exogenous compounds. OATP1A2 is
expressed on the apical membrane of the brain endothelial cells. The expression of
human OATP1A2 on the choroid plexus cells remains to be clarified. In rodents, two
orthologues correspond to the human OATP1A2, Oatp1 and Oatp2. Oatp2 is highly
expressed at both apical and basolateral membranes of the rat brain endothelial cells
(Figure 1-3) while its localization in the choroid plexus is restricted to the basolateral
membrane (Figure 1-4) (Angeletti et al., 1997; Gao et al., 1999). Oatp1 is not expressed
at the BBB but its expression has been detected at the apical membrane of the choroid
plexus (Figure 1-4) (Angeletti et al., 1997; Gao et al., 1999).
Given the high expression levels of OATP1A2 in brain tissue and its broad
spectrum of substrates, it is likely that this transporter play an important role in drug CNS
disposition (Urquhart and Kim, 2009). For example, OATP1A2 was shown to play an
important role in the transport of its substrates of opioid peptides across the BBB (Gao et
al., 2000). Further, brain accumulation of several OATP1A2 substrates was reduced in
mouse model lacking Oatp2 (Ose et al., 2010). Interestingly, several OATP1A2
substrates, such as levofloxacin and methotrexate, are associated with severe CNS
toxicity and thus OATP1A2-mediated transport may partially explain the CNS associated
side effects with these agents (Maeda et al., 2007). In vitro, OATP1A2 has been shown to
increase imatinib intracellular accumulation (Hu et al., 2008). Further investigation is
warranted to elucidate the role of this transporter in disposition of other tyrosine kinase
inhibitors.
1.3. ANTI-CANCER DRUG PENETRATION IN HIGH-GRADE GLIOMAS
1.3.1. The blood-tumor barrier in malignant glioma
In contrast to the tightly regulated BBB in the normal brain, the BBB in highgrade gliomas is structurally and functionally abnormal (Blakeley et al., 2009; Gerstner
and Fine, 2007; Miyagami and Katayama, 2005). Abnormal features develop in response
to the imbalance between the high demand of oxygen and nutrients by the rapidly
proliferating tumor cells and the poor supply capacity of the existing blood vessels. Such
imbalance, coupled with poor tumor lymphatic drainage, leads to a harsh tumor
microenvironment characterized by hypoxia, decreased nutrients, and accumulation of
metabolic wastes (Bergers and Benjamin, 2003; Fukumura and Jain, 2007; Jain, 2005;
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Padera et al., 2002). Tumor cells overcome these unfavorable conditions by upregulating
several proangiogenic factors such as VEGF (Ferrara, 2004), PDGF (Battegay et al.,
1994), and basic fibroblast growth factor (bFGF) (Friesel and Maciag, 1995). All these
factors induce endothelial cell survival, proliferation, and migration by direct interaction
with their receptors expressed on endothelial cells (Ucuzian et al., 2010). Upregulation of
these proangiogenic factors initiates the development of neovasculature through the
process of angiogenesis (Bergers and Benjamin, 2003; Jain et al., 2007).
The newly developed tumor vessels represent a major determinant of glioma
microenvironment and the principle means for anti-cancer drug delivery to the tumor.
Therefore, the structural and functional properties of these vessels will significantly
influence the concentration and distribution of anti-cancer agents throughout the tumor
(Blakeley et al., 2009; Jain, 2005).
While normal vessels consist of an organized network of venules, capillaries, and
arterioles, tumor vessels are characterized by their heterogeneous distribution. Electron
microscopic analysis of tumor endothelial cells in malignant gliomas indicated that they
are composed of immature capillaries (Miyagami and Katayama, 2005). Structurally,
these vessels are tortuous and dilated with abnormal basement membranes (Brown and
Wilson, 2004; Carmeliet and Jain, 2000). Furthermore, tumor vessels lack direct physical
contact with pericytes, which in normal vasculature are known to stabilize the endothelial
cells and regulate their homeostasis and maturation (Figure 1-3) (Eberhard et al., 2000;
Gerhardt and Betsholtz, 2003). Moreover, tumor vessels experience continuous
compression from the rapidly dividing tumor cells (Padera et al., 2004).
These structural defects render tumor vessels leaky with higher permeability when
compared to normal vessels (Dvorak et al., 1995; Dvorak et al., 1999). The leakiness of
tumor vessels will lead to extravasation of plasma components such as fibrin and albumin
to brain ECF leading to increased interstitial fluid pressure, which is exacerbated by
inefficient tumoral lymphatic drainage (Fukumura and Jain, 2007; Padera et al., 2002).
The high interstitial fluid pressure results in tumor associated edema, which is a universal
observation in gliomas and responsible for many of the disease associated symptoms
(Fukumura and Jain, 2007; Papadopoulos et al., 2004).
Because of the aforementioned hyperpermeablity, it is expected that anti-cancer
drugs can accumulate more easily in tumor ECF. This may explain the high anti-cancer
drug penetration reported in several preclinical and clinical trials of high-grade gliomas
where drug accumulation in tumors was generally close, or sometimes higher, to plasma
concentrations indicating a breached BBB. For example, Hofer et al reported high
gefitinib concentrations (>10-fold of the plasma concentrations) in adult GBM patients
(Hofer and Frei, 2007; Hofer et al., 2006). Several clinical and preclinical studies also
reported similar results for other drugs such as methotrexate (Blakeley et al., 2009),
temozolomide (Zhou and Gallo, 2009), topotecan (Carcaboso et al., 2010), and
vincristine (Wang et al., 2010).
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On the other hand, other studies considered poor CNS penetration of several
chemotherapeutics to be a significant factor in the failure of these regimens in treatment
of malignant glioma (Doolittle et al., 2007; Lassman et al., 2005; Motl et al., 2006b;
Muldoon et al., 2007), suggesting that drug tumoral penetration is not solely dependent
on the hyperpermeability of the endothelial cells within the tumor microenvironment but
also depends on the physicochemical properties of the drug.
It is also important to note that only the vessels at the tumor core are considered
hyper-permeable and leaky. The leading tumor edge that invades through brain
parenchyma is thought to make use of the existing normal brain vasculature with a
relatively intact BBB. These intact endothelial cells will limit drug accumulation at the
tumor edge (Fine et al., 2006; Gilbertson and Rich, 2007; Pitz et al., 2011). Thus, anticancer drug concentrations are expected to be higher at the core than at the invasive
proliferative edge of the tumor (Gerstner and Fine, 2007; Pitz et al., 2011). This concept
was supported by a clinical trial assessing paclitaxel concentrations at the tumor core,
tumor periphery, and at the tumor-normal brain interface in high-grade glioma patients.
Highest levels of paclitaxel were found in the tumor core, followed by the tumor
periphery, with lowest paclitaxel concentrations found in the normal surrounding brain
tissue (Fine et al., 2006; Gerstner and Fine, 2007). Improving the delivery of anti-cancer
drugs to the clinically challenging infiltrative tumor cells may improve treatment
outcome of high-grade glioma as these invasive cells represent a clinical challenge and
are considered an important determinant for tumor recurrence (Giese et al., 2003).
1.3.2. The glioma cell barrier
High-grade glioma is composed of three distinct, yet interrelated, compartments.
First, a vascular compartment formed of both existing blood vessels from normal brain
tissue and newly developed tumor vasculature. The second is the ECF compartment, and
the third is the intracellular compartment where most drugs currently used in treatment of
high grade gliomas exert their anti-tumor effect (Baselga, 2006; Hammarlund-Udenaes,
2010; Hammarlund-Udenaes et al., 2008; Reichel, 2009). Though this three-compartment
concept may not reflect the pathological complexity of the tumor, it provides a useful
platform to understand drug trafficking mechanisms within different tumor
compartments.
Anti-cancer drug disposition within these three compartments is determined by
intricate microenvironmental properties of each compartment. Drug diffusion from the
vascular to the ECF compartments is controlled by the leakiness of the vessels as well as
the high interstitial fluid pressure. On one hand, anti-cancer agents may diffuse from the
leaky tumor vessels and accumulate in tumor ECF compartment (Blakeley et al., 2009;
Carcaboso et al., 2010; Hofer and Frei, 2007; Hofer et al., 2006; Zhou and Gallo, 2009).
On the other hand, the lack of pressure difference between the vascular and interstitial
fluid compartments, as a result of the high interstitial fluid pressure, may lead to a
stagnant blood flow which will limit drug accumulation in tumor ECF (Fukumura and
Jain, 2007).
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Several studies assessing anti-cancer drug penetration at the tumor core of highgrade glioma ECF show high tumor penetration ratio relative to plasma concentrations
(Blakeley et al., 2009; Carcaboso et al., 2010). This suggests that anti-cancer agents are
capable of reaching the tumor ECF. Determining whether the anti-cancer drug
concentration achieved within the tumor is therapeutically effective requires determining
the unbound drug concentrations at the active site. Most anti-cancer agents currently used
for treatment of high-grade glioma exert their anti-tumor effect by interacting with
intracellular targets. Even drugs that target receptor tyrosine kinases expressed on tumor
cell membranes often interact with cytoplasmic domains of their targets and thus require
intracellular accumulation of these agents (reviewed in Baselga, 2006).
Efflux transporters expressed on glioma cell membranes restrict intracellular
accumulation of anti-cancer drugs and therefore provides an additional barrier (Agarwal
et al., 2011b; Lee et al., 2001). Several reports showed the expression of P-gp
(Calatozzolo et al., 2005; Decleves et al., 2002; Demeule et al., 2001; Fattori et al., 2007;
Nabors et al., 1991), BCRP (Carcaboso et al., 2010; Decleves et al., 2006), as well as
MRPs 1 and 4 (Bronger et al., 2005; Calatozzolo et al., 2005; Decleves et al., 2002;
Mohri et al., 2000) in cases of malignant glioma.
Due to the effect of efflux transporters on glioma cell membrane, anti-cancer
drugs may accumulate in the ECF compartment while only a fraction of the drug can
accumulate inside the tumor cell (Carcaboso et al., 2010). Furthermore, only a fraction of
the drug that reaches the intracellular compartment will be free to interact with its target
while the rest remains nonspecifically bound to intracellular lipids and proteins
(Hammarlund-Udenaes et al., 2008; Reichel, 2009). This will further reduce the amount
of drug available to exert anti-tumor effect (Hammarlund-Udenaes, 2010; HammarlundUdenaes et al., 2008; Maurer et al., 2005; Reichel, 2009). Unfortunately, very little
information is known about intracellular drug accumulation due to the difficulty of
sampling the intracellular compartment in vivo. Thus, determining whether
therapeutically effective concentrations can be achieved at the target site cannot be
directly assessed in vivo using currently available methodologies (Hammarlund-Udenaes
et al., 2008; Reichel, 2009).
Most of the studies assessing anti-cancer tumoral penetration rely on brain
homogenization techniques. Several of these studies reported high tumor penetration
profiles of anti-cancer drugs relative to plasma concentrations (e.g., gefitinib tumor
concentrations reported to be more than 10-fold higher than that of the plasma
concentrations) (Hofer and Frei, 2007). The techniques applied in these studies do not
discern between any of the three tumor compartments. They also do not account for
binding of the drug to proteins either in plasma or in tumor tissue. Therefore, no
conclusions can be made regarding whether the achieved concentrations of the unbound
drug at the target site are effective or not.
A study conducted by our group assessing intracellular topotecan distribution by
analyzing both total and ECF concentrations in an orthotopic xenograft mouse model of
glioma showed an inverse correlation between ECF concentrations and intracellular
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distribution (i.e., higher ECF concentrations correlate with lower intracellular
distribution). Inhibiting efflux transporters, specifically P-gp and BCRP, at the tumor cell
membrane decreased topotecan ECF concentrations and increased its intracellular
distribution, indicating a critical role of efflux transporters in limiting anti-cancer drug
access to the intracellular compartment (Carcaboso et al., 2010).
The complexity of assessing anti-cancer drug penetration in different tumoral
compartments underscores the importance of understanding the different methods used to
sample each compartment as well as the need for clinically relevant animal models that
recapitulate features of the human disease. In the next two sections, animal models of
high grade glioma currently available to study anti-cancer drug penetration and the
approaches used to evaluate drug penetration within the tumor will be discussed.
1.4. MURINE MODELS OF MALIGNANT GLIOMA
The need for clinically relevant murine models of high-grade glioma is
compelling. Such models will allow researchers to translate their findings from
preclinical experiments to the bedside. The ideal murine model for studying anti-cancer
drug accumulation in glial tumors should accurately recapitulate the histological features
of high-grade glioma including hypoxia, intense vascular proliferation, and the invasive
growth pattern of these tumors. This model should also reflect the interaction between the
tumor and host stroma. Tumors in such an ideal model should have high penetrance and a
reasonable latency that allows growth of tumors within adequate period that reflects, even
partially, the human disease while still providing a window for testing of anti-cancer
agents before the animals become moribund. Finally, such a model should mimic the
genetic profile of high-grade glioma observed in patients.
Despite the availability of several murine models of malignant glioma, an ideal
model that recapitulates all aspects of the disease does not exist. Every model provides a
set of advantages and disadvantages to the research question. Depending on the purpose
of the experiment, investigators should weigh the pros and cons of the models available
and decide which model provides an adequate recapitulation of important effectors
regarding their experiment. In this section, the pros and cons of some of the available
models will be discussed with emphasis on their relevance to glioma histology, tumor
microenvironment, genetic representation, and their suitability for drug penetration
studies.
1.4.1. Subcutaneous xenograft models
Due to their relatively short latency, ease of establishment, predictable growth
pattern, and the simplicity of monitoring tumor growth without the need for complex
imaging techniques, subcutaneously implanted xenograft models are widely used for
monitoring tumor response to chemotherapeutic regimens. Tumors implanted in these
models commonly display features of hypoxia (Gillespie et al., 2007) and the
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development of neovasculature (Kim et al., 1993; Saleh et al., 1996). However,
subcutaneous tumors fail to provide adequate resemblance to the microenvironment or
growth pattern of intracranial glioma tumors in humans. For example, subcutaneously
implanted models do not acquire the invasive growth characteristics of high-grade
gliomas and grow mainly as a “bag” of tumor cells, bearing no resemblance to glial
tumors (Antunes et al., 2000).
Further, the gene expression profiles of glioma cell lines implanted
subcutaneously in nude mice was significantly different from intracranial tumors
established from the same cell lines (Camphausen et al., 2005a; b). This indicates that
subcutaneous growth of subcutaneous tumors provides different and probably irrelevant
in vivo growth conditions (Camphausen et al., 2005a; b).
The use of these models to determine drug tumoral penetration is inadequate as
these models neither recapitulate the degree of high-grade glioma microvascular
proliferation nor the different CNS barriers against drug penetration (de Vries et al.,
2009). This is supported by reports showing different penetration profiles of anti-cancer
drugs in subcutaneous tumors when compared to their orthotopic counterparts (Ma et al.,
2003). Consequently, anti-cancer drug penetration studies conducted using subcutaneous
xenograft models are not indicative of the intracranial tumor situation and thus these
models should not be used to study CNS drug penetration.
1.4.2. Orthotopic xenograft models
The relative ease of engraftment, rapid tumor growth, and short latency from
tumor inoculation until morbidity have made orthotopic xenograft models an essential
tool for in vivo efficacy studies of anti-cancer drugs in the past decade. These models are
considered more appropriate than subcutaneous xenograft models in predicting drug
efficacy and CNS drug penetration. However, concerns have been expressed regarding
the clinical relevance of the tumor microenvironment in these models and whether they
represent accurate models to study anti-cancer drug penetration to glial tumors.
Although some orthotopic xenograft models provide adequate recapitulation of
the histological and invasive properties of malignant gliomas (e.g., U251) (Houchens et
al., 1983; Radaelli et al., 2009), many commonly used models fail to recapitulate any of
these properties (Becher and Holland, 2006; Jacobs et al., 2011). For example, upon
intracranial inoculation of U87–MG cells in immune compromised mice, huge
circumscribed tumors with clear tumor edge separating the tumor tissue from the
surrounding normal brain are formed (Carcaboso et al., 2010; de Vries et al., 2009;
Radaelli et al., 2009). As mentioned earlier, this growth pattern is vastly different from
that of infiltrative tumors observed in patients (Giese et al., 2003). Unfortunately,
U87-MG cell line has been one of the most frequently used cell lines for xenograft
studies. This cell line has significantly contributed, perhaps in a biased way, to our
understanding of high-grade gliomas.
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Another pitfall of xenograft models in general is their reliance on in vitro
culturing of tumor cells. Cells are cultured on plastic plates or flasks may acquire or lose
novel genetic properties (Camphausen et al., 2005a; b; Kucherlapati, 2012). For example,
GBM cell lines cultured in vitro cannot preserve EGFR focal amplification, a common
genetic alteration in ~50% of adult patients with GBM (Pandita et al., 2004). Attempts to
preserve the genetic properties of the original tumor included direct implantation of
tumors from patients in immune-compromised mice (Pandita et al., 2004). Other trials
focused on in vitro culturing of primary tumor cells under serum-free neurobasal media
supplemented with different concentrations of growth factors such as EGF and bFGF
instead of serum-based culture conditions (Lee et al., 2006; Schulte et al., 2012). Further
studies are required to demonstrate the benefit of these approaches on recapitulating the
features of the original tumor (Schulte et al., 2012).
Importantly, a tumor implanted in an immune compromised host lacks the
contribution of the host-tumor interaction, which may impact the tumor propensity to
invade, metastasize, and develop new blood vessels (Becher and Holland, 2006). This
may explain the inability of several orthotopic glioma models to recapitulate many of the
histological features of HGGs including the invasiveness and the intense microvascular
proliferation.
Orthotopic xenograft models are used, almost exclusively, for drug penetration
studies in high-grade gliomas as they provide some depiction of the different CNS
barriers (Carcaboso et al., 2010; Ma et al., 2003). Some inherent limitations of these
models are unlikely to be avoided such as the genetic properties acquired on culture and
the inability to recapitulate the host-tumor interaction. However, adequate orthotopic
models for drug penetration studies should recapitulate tumor invasiveness and
microvascular proliferation observed in human tumors. In general, the data obtained
using these models should be interpreted in light of the limitations discussed earlier.
1.4.3. Genetically engineered mouse models
Given all the aforementioned shortcomings of glioma xenograft models together
with the advancements in gene targeting technologies, more focus has been directed to
develop genetically engineered mouse models (GEMMs) that can represent the genetic
profile and histological features of high-grade glioma including the invasive growth
pattern of these tumors. In general, these models reproduce the microenvironment of
high-grade glial tumors better than xenograft models (Becher and Holland, 2006; Chow
and Baker, 2012; Kucherlapati, 2012).
GEMMs can be categorized into germ-line and somatic GEMMs. In germ-line
GEMMs, genetic alterations are introduced in the embryonic stage and is maintained
through breeding (Aguzzi et al., 1994; Heyer et al., 2010). Germ-line GEMMs are
beyond the scope of our discussion. The reader is directed to several excellent research
articles and reviews where germ-line GEMMs have been discussed in more detail (de
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Vries et al., 2009; Ding et al., 2001; Reilly et al., 2000; Wang et al., 2009; Xiao et al.,
2002; Zhu et al., 2005).
Somatic GEMMs harbor genetic alterations in some of its somatic cells but not in
the germ line cells. Of these, conditional GEMMs enable the induction of the genetic
event in a temporally and spatially controlled manner (i.e., the genetic alteration can be
induced at a certain time during the mouse development and in a certain subset of cells
(Gossen and Bujard, 1992; Heyer et al., 2010). In this section, we will highlight some of
the recently reported somatic GEMMs that may provide reasonable tools for studying
anti-cancer drug penetration in high-grade gliomas.
Marumoto and colleagues reported a novel GEMM that recapitulates most
features of high-grade gliomas (Marumoto et al., 2009). Tumors develop upon
stereotactic injection of lentiviral vectors expressing H-RasV12 and AKT oncogenes in
immune compromised mice with GFAP-Cre/p53+/- background that restricts the
expression of H-RasV12 and AKT oncogenes to GFAP (glial fibrillary acidic protein)
expressing cells, i.e. astrocytes and neural progenitor cells. Tumors can be established in
different brain locations with variable degree of penetrance (hippocampus 100%,
subventricular zone 75%, and the cortex 7%) (Marumoto et al., 2009).
The genetic drivers of this model are different from that observed in patients.
While RTK/PI3K pathway is frequently deregulated in gliomas (Guha et al., 1997;
Pollack et al.), Ras mutation and AKT amplification are relatively rare events in highgrade gliomas (~2% for each) (TCGA, 2008). Other concerns noted about the viral
delivery approach include unpredictable delivery and efficiency which may result in
different cell groups transduced with either one of these oncogenes (Ras and AKT) or
both leading to multiple tumor types in the same mouse (de Vries et al., 2009; Heyer et
al., 2010). Finally, the contribution of the host immune response to tumor growth is
lacking in this model as tumors are generated in immune compromised mice (Marumoto
et al., 2009).
Tumors of this model showed many of the histological features of high-grade
gliomas including high cellularity, necrosis, invasiveness through brain parenchyma, and
a high degree of vascular proliferation. Reasonable latency (~ 3 months) was observed
for the development of these tumors. These properties render this model a reasonable
model to study anti-cancer drug penetration in glioma (Marumoto et al., 2009).
Another recently reported model involves intracranial injection of GFAP-Cre or
CMV-Cre in compound LoxP-conditional mice with p53 or pten deletions (de Vries et
al., 2010). Viral transduction of Cre leads to K-RasV12 expression and deletion of the
tumor suppressor gene Ink4a/Arf, resulting in high-grade astrocytoma with 100%
penetrance. These tumors demonstrate most of the histological features of high-grade
glioma tumors with increased mitosis, nuclear atypia, giant cell formation, and
pseudopalisading necrosis. Tumor vessels of this model express BCRP, a feature
observed in vessels from human glioblastoma (Zhang et al., 2003). Since these tumors are
luciferase-labeled, their growth can be easily monitored using bioluminescence.
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As noted in the previous model, Ras mutations are rare genetic events in glioma
and thus the genetics of this model might not be representative of the human disease.
However, this model presents a useful tool which combines the relative ease of induction,
simple monitoring of tumor growth, and retaining important markers of tumor
vasculature (de Vries et al., 2010). Unfortunately, this model did not show glioma-like
angiogenic features and thus lacks an important determinant of tumoral drug penetration
in high-grade glioma.
Another tumor model to induce conditional loss of function is the inducible
CreERTM-loxP system, which allows temporal and spatial control of somatic deletion of
tumor suppressor genes (Gossen and Bujard, 1992; Jonkers and Berns, 2002). Cre
recombinase is expressed under the control of the promoter of a site-specific marker (e.g.,
GFAP in case of astrocytes and neural precursors). Administering the inducer (e.g.,
tamoxifen) will result in nuclear translocation of the Cre recombinase, which induces
somatic deletion of “floxed” tumor suppressor genes (Metzger and Feil, 1999; Pluck,
1996).
Few glioma models using this system have been reported. For example, Liaguno
and colleagues showed that deletion of tumor suppressor genes Nf1, p53, and/or Pten in
Nestin-expressing cells lead to development of high-grade gliomas (Alcantara Llaguno et
al., 2009). Tumors of this model showed all of the typical histological features of highgrade gliomas within ~4 months of induction with 100% penetrance. Finally, Chow et al
used CreERTM-loxP system to show that deletion of p53, Pten, and Rb results in initiation
of high-grade astrocytoma with high penetrance (~85%) (Chow and Baker, 2012; Chow
et al., 2011).
Both CreERTM-loxP dependent models discussed above bestow many of the
genetic and histological features of malignant glioma. Another point to note is the
heterogeneity associated with the tumor location, histology, and the secondary
spontaneous mutations associated with these models (Alcantara Llaguno et al., 2009;
Chow et al., 2011). While this feature provides better recapitulation of the heterogeneous
nature of malignant glioma, it adds more complexity to conducting preclinical
experiments and interpreting the results. Other pitfalls of these models are the relatively
long latency of tumor growth (~4-6 months) and the relative difficulty of monitoring in
situ tumor growth. However, with better experimental design in monitoring tumor growth
and location, the use of novel imaging modalities such as MRI, and careful scheduling of
experiments before animals succumb to disease, these models can provide an attractive
tool to study anti-cancer drug penetration to high-grade glioma.
1.5. APPROACHES TO EVALUATE ANTI-CANCER DRUG PENETRATION
IN BRAIN TUMORS
The extent of drug penetration within brain tumors can be calculated as the ratio
of unbound drug concentrations in the tumor relative to unbound concentrations in the
plasma at steady state, or by the ratio of unbound area under the curve (AUC) in tumor
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relative to unbound plasma AUC. Different sampling strategies and pharmacokinetic
approaches have been used to determine tumoral drug penetration. These methods differ
in the number of samples that can be obtained, their ability to provide compartmentspecific information about drug penetration, and their ability to account for drug protein
binding. In this section, the pros and cons of these methods will be briefly discussed.
1.5.1. Whole tissue homogenization
Due to the ease of sample collection and processing, most preclinical and clinical
studies have relied on homogenizing whole brain or tumor samples to study anti-cancer
drug concentration expressed as the amount of drug per gram tissue (e.g., ng/gm tissue)
(Hofer and Frei, 2007; Hofer et al., 2006; Lassman et al., 2005; Zhou and Gallo, 2009).
In preclinical studies, this method involves sacrificing 3-6 animals per time point and
collecting blood and tissue at each time point. Therefore, large numbers of animals are
required, typically around 25-40 animals per study (Zhou and Gallo, 2009). In clinical
studies, tumor tissue can be collected only during surgical removal of the tumor and thus
only one time point can be studied in each patient.
This method does not discern between different tumor compartments (e.g.,
vascular, ECF, and intracellular), and consequently fails to provide information about
anti-cancer drug concentration within any specific compartment. This method considers
the tumor one homogenous entity and thus provides the total drug concentration in all
tumor compartments.
Another limitation to tumor homogenization is that it does not account for drug
binding to the tumor tissue. Only unbound drug can pass through the barriers, enter tumor
cells, bind to its target and exert the anti-tumor effect (de Lange and Danhof, 2002; Smith
et al., 2010). High total drug concentration in the tumor (Atumor) can be misleading, as it
does not necessarily reflect high pharmacologically available concentrations at the active
site. In other words, Atumor may reflect drug in the vascular compartment, ECF
compartment, or even drug bound to nonspecific, off target intracellular proteins. It is
also important to mention that binding of the drug in brain or tumor is different from that
in plasma due to different protein and lipid contents between plasma and brain
(Richmond, 1985).
1.5.2. CSF Sampling
CSF sampling is an alternative method to study CNS and tumor drug disposition
(Shen et al., 2004). This method provides information on the unbound drug
concentrations (Lin, 2008). As discussed earlier, CSF is separated from the blood via the
BCSFB, which is mainly dependent on efflux transporters expressed at either apical or
abluminal sides of the choroid plexus (Motl et al., 2006a). CSF sampling is commonly
obtained through a procedure known as lumbar puncture which usually provides a single
CSF sample (Hill et al., 1999). However, for serial sampling a cannula should be inserted
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in the cisterna magna (Bruce and Oldfield, 1988; Schumann and Crisman, 1985). Given
the ease of obtaining serial samples from this method, several preclinical and clinical
studies relied on CSF sampling as a surrogate for brain or tumor concentrations (Blaney
et al., 1998; Broniscer et al., 2007b; Vanbree et al., 1989; Vistelle et al., 1994).
However, evidence from several reports suggests that CSF concentrations are
poor surrogates of brain ECF concentrations (de Lange and Danhof, 2002; Lin, 2008).
For example, several P-gp substrates exhibit different penetration profiles in brain ECF
compared to CSF (Shen et al., 2009). This can be explained by P-gp localization at the
BBB and the BCSFB, which allows P-gp to transport its substrates from brain ECF to
blood at the BBB and into the ventricular CSF at the BCSFB. Similar reports showing
different CSF and ECF penetration of several other drugs are available (e.g. morphine,
nelfinavir, and antipyrine) (Kaddoumi et al., 2007; Mayer et al., 1959; Stain-Texier et al.,
1999). Further, the increased BBB permeability observed at the core of high-grade
glioma tumors is likely to cause different penetration profiles in tumor ECF than in CSF,
which means that CSF concentrations cannot be used as a surrogate to estimate tumor
ECF concentrations (Stain-Texier et al., 1999).
1.5.3. Cerebral microdialysis
Cerebral microdialysis is a sampling technique that involves the insertion of a
semi-permeable probe into the target tissue (e.g., brain or tumor). This probe is then
perfused by a solution (i.e. perfusate) that mimics the composition of the target tissue
(e.g., ECF or CSF). Molecules (e.g., anti-cancer drug) in the target tissue will diffuse
through the semi-permeable membrane according to their concentration gradient. Finally,
the collected sample (i.e. dialysate) is analyzed using analytical methods sensitive enough
to detect the drug in the small sample volume collected.
Microdialysis provides a useful tool to sample a distinct tissue compartment, the
ECF or ventricular CSF. An important advantage of this technique is that only unbound
drug can pass through the pores of the semi-permeable membrane given the low
molecular weight cutoff of the probe (~ 5 kDa) (Tsai, 2003). Therefore, inserting a
microdialysis probe in the tumor can allow investigators to determine the unbound
(active) drug concentration in the ECF (Tsai, 2003). It also allows serial sampling from a
single animal, thus reducing the number of animals required for preclinical studies (de
Lange et al., 1997; Hammarlund-Udenaes et al., 1997).
Microdialysis is used for ECF sampling for analysis of a single anti-cancer agent.
However, the resistant nature of some CNS tumors renders combination regimens a
plausible approach to overcome tumor resistance (Brown et al., 2008; Fan and Weiss,
2010; Karpel-Massler et al., 2011; Krakstad and Chekenya, 2010; Prados et al., 2006). To
our knowledge, no studies have been published that show the feasibility of simultaneous
microdialysis sampling of multiple anti-cancer agents. Thus, a robust method to
simultaneously sample multiple anti-cancer agents coupled with sensitive analytical
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methods can prove useful in determining the penetration profile of anti-cancer agents
administered in combination.
Microdialysis has many advantages over other methods to assess CNS drug
disposition, but it does have limitations. A limitation of microdialysis is the trauma
associated with surgical insertion of the probe in the tissue. This raises some concerns to
whether inserting the probe may damage the endothelial cells of the BBB and thus limit
the suitability of microdialysis to study BBB-related questions. Several studies have
evaluated the trauma associated with implanting a microdialysis probe. For example,
cerebral blood flow was disturbed 2 hours after probe implantation in rat brains. After 24
hours, cerebral blood flow is restored and no major disturbances could be detected
(Benveniste et al., 1987). For cerebral tumors, implanting microdialysis probes showed
no signs of inflammation for ~ 3 days. After 3 days of implantation, a mild tissue reaction
manifested as gliosis was detected around the probe. This reaction was shown not to
affect BBB transport (de Lange et al., 1994). Generally, histological evaluation
performed in several microdialysis studies showed only mild tissue trauma, if any, after
probe implantation, which is not likely to affect BBB integrity (Carcaboso et al., 2010;
Elmeliegy et al., 2011a; Elmeliegy et al., 2011b). Finally, if probe implantation damages
the BBB, one would speculate that substances that typically cannot penetrate to the brain
would show higher brain accumulation after probe implantation. However, brain
accumulation of integrity markers such as fluorescein dextran and 14C-alpha-aminoisobutyric acid was not increased after probe implantation indicating that BBB integrity
was preserved (Benveniste et al., 1984; de Lange et al., 1998).
Several microdialysis studies have been conducted in orthotopic glioma
xenografts (Ma et al., 2003; Ma et al., 2001). However, GEMMs have never been used in
microdialysis studies. Several reasons may contribute to the difficulty of using GEMMs
in microdialysis studies. One reason is the need for complex and costly imaging
techniques to determine brain tumor location. Such expensive imaging modalities (e.g.
MRI) are not necessarily available in all research institutes.
Another reason is the technical challenge of implanting the microdialysis cannula
and probe in the spontaneously developed tumor given the heterogeneity commonly
associated with these models. Implanting microdialysis cannulas in orthotopic xenograft
models is relatively easy and can be established by stereotactically injecting tumor cells
followed by microdialysis cannula/probe using the intersection between the coronal and
sagittal sutures, i.e. the bregma point, as a reference point (Carcaboso et al., 2010; Ma et
al., 2003). However, the bregma point does not appear on images derived by MRI. The
lack of common reference points between the MRI images and the mouse skull renders
accurate determination of implantation coordinates in GEMMs rather challenging. New
methodologies to guide microdialysis cannula implantation using a reference point visible
on MRI may prove useful for CNS penetration studies in GEMMs.
Another limitation that prevented the use of cerebral microdialysis in GEMMs is
that, in many cases identification of the tumor can only be accomplished at a late stage at
which surgical implantation of the cannula and performing the microdialysis experiment
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is technically not feasible. These problems can be addressed using novel imaging
techniques such as MRI to identify the tumor location prior to surgically implanting the
cannula.
During a microdialysis experiment, drug concentration in tissue ECF is more than
in the perfusate and therefore true equilibrium conditions cannot be achieved. Thus,
concentrations in the dialysate will be different from that in tissue ECF. Therefore,
relating dialysate concentrations to tissue ECF concentrations, i.e. estimating the extent
of drug recovery from tissue ECF through the probe, is an important step in the design of
the microdialysis experiment. Several methods to calculate probe recovery have been
reported (reviewed in de Lange et al., 1997). We will limit our discussion to two of the
major recovery determination methods, namely retrodialysis and zero flow rate.
1.5.3.1. Retrodialysis
In this method, a known concentration of the drug is prepared in the perfusate and
pumped through the probe. The basic assumption of the retrodialysis method is that the
diffusion process across the microdialysis probe is quantitatively equal in both directions
i.e. the percentage of the analyte lost from the perfusate to the medium is equal to the
percentage recovered from the medium to the perfusate (Figure 1-5) (Wang et al.,
1993b). This method should be conducted when there is no drug present in the body, e.g.
before administering the drug.
1.5.3.2. Zero flow rate
The extent of recovery is inversely proportional to the flow rate of the perfusate
i.e. the lower the flow rate, the higher the probe recovery (Jacobson and Hamberger,
1985; Johnson and Justice, 1983; Lindefors et al., 1989). The zero flow rate (ZFR)
method is applied by collecting dialysates at several flow rates, measuring different
dialysate concentrations, and plotting the concentrations against the flow rate. The basic
hypothesis of this method is that extrapolation to a hypothetical flow rate of zero provides
an estimate of the absolute drug concentration in tissue ECF (Jacobson et al., 1985). The
ZFR requires drug concentration to remain relatively constant while collecting the
dialysates at different flow rates (Jacobson et al., 1985).
1.6.

SUMMARY

For the past three decades, little progress has been achieved in the treatment of
malignant glioma in both adults and pediatric populations. The recent advances in tumor
genotyping identified important genetic alterations in disease development and
progression. However, several clinical trials showed that molecularly targeted agents that
target these genetic alterations failed to provide significant therapeutic benefit for
malignant glioma patients. Inadequate penetration of these agents to the tumor may
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Figure 1-5.

Diagrammatic illustration of the retrodialysis method

Retrodialysis experiment (upper panel) is conducted by perfusing drug prepared
in perfusate (Cin) through the probe. A fraction of the drug will be lost across the
probe. Percent of drug lost through probe can be calculated as
100 X
. The underlying assumption of this method is that the
percentage of drug lost across the membrane is equal to that gained from the
tissue ECF during the experiment (lower panel).
Source: Reprinted by permission from Elsevier. de Lange et al. (2000)
Methodological issues in microdialysis sampling for pharmacokinetic studies.
Advanced Drug Delivery Reviews 45:125-148.

32

partially explain the failure encountered in the clinics. Delivery of these agents to the
tumor can be influenced by several efflux and uptake transporters expressed at the BBB
and the BCSFB. Through this project, we investigated the effect of major efflux and
uptake transporters at the BBB and the BCSFB on the penetration of two tyrosine kinase
inhibitors, erlotinib and crenolanib. We also studied erlotinib and crenolanib penetration
in murine models of high-grade glioma using cerebral microdialysis.
1.7.

SPECIFIC AIMS

The objective of specific aim 1 was to assess the role of efflux and uptake
transporters in erlotinib CNS penetration and intracellular accumulation.
The objective of specific aim 2 was to use MRI imaging to identify a reference
point for implanting microdialysis cannula in spontaneously arising tumors in a GEMM
for high-grade glioma.
The objective of specific aim 3 was to demonstrate the feasibility of simultaneous
sampling of multiple anti-cancer agents, erlotinib and crenolanib, via cerebral
microdialysis.
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CHAPTER 2. ROLE OF ATP-BINDING CASSETTE AND SOLUTE CARRIER
TRANSPORTERS IN ERLOTINIB CNS PENETRATION AND
INTRACELLULAR ACCUMULATION*
2.1.

INTRODUCTION

Erlotinib (TarcevaTM) is an orally administered epidermal growth factor receptor
(EGFR) inhibitor approved for certain types of non-small cell lung cancer (NSCLC) and
pancreatic cancer (Shepherd et al., 2005). In humans, erlotinib is extensively metabolized
primarily by hepatic CYP3A4 and CYP3A5 with some metabolism by CYP1A2 and
CYP2C8 (Ling et al., 2006). The metabolite, OSI-420, retains EGFR tyrosine kinase
inhibitory activity as well as in vivo tumor growth inhibitory activity (Moyer et al.,
1997).
Clinical trials have evaluated the safety and activity of erlotinib in patients with
primary and secondary central nervous system (CNS) tumors with frequent EGFR
alterations, such as high-grade glioma and brain metastases of NSCLC (Broniscer et al.,
2009; Sun et al., 2009). In most of these studies, erlotinib failed to show clinically
significant activity (Broniscer et al., 2009; Shepherd et al., 2005; van den Bent et al.,
2009a). A potential explanation for this lack of efficacy is that the BBB prevents the
accumulation of effective erlotinib concentrations in the tumor (Loscher and Potschka,
2005; Shen et al., 2004). This is supported by evidence from clinical studies showing low
erlotinib and OSI-420 accumulation in high-grade glioma (Lassman et al., 2005; Raizer et
al., 2010a).
One mechanism by which the BBB limits erlotinib CNS penetration is the
expression of efflux proteins of the ATP-binding cassette (ABC) transporter family at the
brain endothelial cells (Giacomini et al., 2010). ABC transporters likely to impede
erlotinib CNS distribution include P-glycoprotein (P-gp/MDR1/ABCB1; Mdr1a/b in
mice), breast cancer resistance protein (BCRP/ABCG2; Bcrp1/Abcg2 in mice), and the
multidrug resistance-associated protein 4 (MRP4/ABCC4; Mrp4/Abcc4 in mice)
(Kodaira et al., 2010; Leggas et al., 2004a). Expression of efflux transporters on tumor
cell membranes would be an additional mechanism of drug resistance preventing the
intracellular penetration of anti-cancer drugs (Carcaboso et al., 2010).
In addition to ABC transporters, uptake transporters located at the BBB or at the
blood-tumor barrier could also regulate drug delivery to the CNS and brain tumors (Ose
et al., 2010). Several uptake transporters of the SLC22A family are localized at the BBB
or at the blood cerebrospinal fluid barrier (BCSFB) where they affect the disposition of
*Reprinted with permission. Elmeliegy MA et al. (2011) Role of ATP-binding cassette
and solute carrier transporters in erlotinib CNS penetration and intracellular
accumulation. Clin Cancer Res 17:89-99.
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their substrates (Kikuchi et al., 2003; Kusuhara and Sugiyama, 2005; Lin et al., 2010;
Nagata et al., 2002).
The expression of some uptake transporters is detected in vessels of high-grade
glioma where they may affect drug accumulation inside the tumor (Bronger et al., 2005).
However, the affinity of these transporters towards many anti-cancer agents, including
erlotinib, has not been studied.
Erlotinib concentrations in the cerebrospinal fluid (CSF) of patients with brain
tumors have been previously reported as 8% of the total plasma concentration (Broniscer
et al., 2007b; Togashi et al.). However, several studies in animals have demonstrated
differential (usually increased) drug distribution in the CSF as compared to the brain
parenchyma extracellular fluid (ECF) (Kaddoumi et al., 2007; Shen et al., 2009; StainTexier et al., 1999), emphasizing the limitations of using CSF sampling, or whole brain
homogenates, to examine CNS drug penetration.
In the present study, we used cerebral microdialysis sampling to assess the role of
murine ABC transporters Bcrp1, P-gp, and Mrp4 in CNS penetration of erlotinib and
OSI-420. Furthermore, we used a panel of cell lines expressing human efflux or uptake
transporters to investigate transport processes involved in CNS penetration and
intracellular accumulation of erlotinib and OSI-420.
2.2.

MATERIALS AND METHODS

2.2.1. Animals
Animals used were wild-type FVB, Abcg2-/-, Mdr1a/b-/-, Abcc4-/-, and Mdr1a/b-/Abcg2-/- mice. All mice were on a FVB genetic background, 3-4 month old, females, and
provided by Taconic (Hudson, NY; except Abcc4-/-, obtained at SJCRH). All animal
studies were conducted using protocols and conditions approved by the Institutional
Animal Care and Use Committee.
2.2.2. Chemicals and reagents
GF120918 was purchased from API (China). Erlotinib, OSI-420 analytical
standards, and the internal standards for each compound used in the mass spectrometry
assay were kindly provided by OSI pharmaceuticals (Uniondale, NY).
2-Hydroxypropyl-β-cyclodextrin (HPBCD) was purchased from CTD, Inc. (High
Springs, FL).
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2.2.3. Cell lines
The porcine kidney epithelial LLC-PK1 cell line and the L-MDR1 cell lines
stably expressing human ABCB1 were cultured in DMEM, 10% fetal bovine serum,
penicillin 100 U/ mL and streptomycin 100 µg/mL; all from Invitrogen (Carlsbad, CA).
Saos2 cells containing pcDNA3.1 empty vector, ABCG2, or ABCC4 were maintained in
DMEM containing 10% fetal bovine serum, penicillin (100 U/mL), streptomycin (100
µg/mL), and G418 sulfate (500 µg/mL; Invitrogen). HEK-293 cells stably transfected
with OCT1, OCT2 (Hayer-Zillgen et al., 2002), OAT1, OAT2, OAT3 (Tahara et al.,
2006), OCTN1, and OCTN2 (Nezu et al., 1999), along with pcDNA vector–transfected
controls were cultured in DMEM supplemented with 10% fetal bovine serum and G418
sulfate (400-800 µg/mL).
2.2.4. Determination of erlotinib and OSI-420 protein binding in mouse plasma
Erlotinib and OSI-420 were added to mouse plasma (Hiltop, Scottdale, PA) to
make final erlotinib and OSI-420 concentrations of 1, 2, and 4 µg/mL. 200 uL of plasma
were added to each well of a 96-well equilibrium dialysis plate (Harvard Apparatus, MA)
and incubated on a rotator at 37°C. Samples were collected from plasma and PBS buffer
chambers at several time points after starting the experiment. Samples were analyzed
using a validated liquid chromatography/mass spectrometry (LC/MS) method (Zhao et
al., 2003). Unbound fraction (fu) of either erlotinib or OSI-420 was calculated as follows:
fu =

CPBS
CPlasma

where CPBS and CPlasma are the concentrations of erlotinib or OSI-420 in PBS and plasma,
respectively. To compare the unbound fraction of erlotinib and OSI-420 in different
strains, plasma was isolated from each strain and equilibrium dialysis was performed as
previously described.
2.2.5. Erlotinib and OSI-420 plasma pharmacokinetics
A single erlotinib dose was administered to all five strains of mice (n = 8-13 mice
per group). To administer erlotinib, TarcevaTM (OSI Pharmaceuticals, Uniondale, NY)
tablets were pulverized and suspended in 0.2% carboxymethylcellulose and 0.05%
Tween 20, for a final concentration of 5 mg/mL. The erlotinib suspension was
administered at a dosage of 50 mg/kg by oral gavage. Plasma samples were taken by
retro-orbital bleeding at 7 time points after drug administration (5 minutes, 0.5 hrs, 1, 2,
6, 12, and 24 hours). At least four different animals contributed to each time point. Blood
samples were centrifuged at 3000 rpm for 3 minutes. Plasma samples were immediately
stored at -80°C till further analysis using liquid chromatography/tandem mass
spectrometry (LC MS/MS) (Zhao et al., 2003).
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2.2.6. Development of pharmacokinetic limited sampling models for erlotinib and
OSI-420
Data from the plasma pharmacokinetic experiment were analyzed with nonlinear
mixed-effects modeling using the importance sampling EM algorithm in NONMEM VII
(Beal and Sheiner, 1980). A model with one compartment for erlotinib and one
compartment for OSI-420 and first-order conversion from erlotinib to OSI-420 and firstorder elimination of OSI-420 was used to fit the plasma concentration-time data. Models
with first-order absorption, zero-order absorption and sequential zero-order and firstorder absorption were tested. The appropriate model was chosen based on objective
function value (OFV) and inspection of goodness-of-fit plots. The estimated parameters
included the duration of zero-order infusion (D1), first-order absorption rate constant (ka)
apparent oral clearance of erlotinib (CLERL/F), apparent volume of distribution of
erlotinib (VERL/F), apparent clearance of OSI-420 (CLOSI/FE), and apparent volume of
distribution of OSI-420 (VOSI/FE), where F is the bioavailability and FE is the fraction of
erlotinib converted to OSI-420. Inter-individual variability (IIV) terms were added to the
CLERL/F, VERL/F, CLOSI/FE, and D1 parameters. IIV was modeled as a log-normal
distribution and a proportional error model was used for residual variability.
Data below the lower limit of quantitation of 1 ng/mL were included in the
analysis with a likelihood-based approach using method M3 as previously described
(Ahn et al., 2008). Each strain of mice was analyzed separately, and the model
parameters were used to develop a limited sampling strategy using the D-optimality
algorithm in ADAPT 5 (D'argenio et al., 2009). The limited sampling strategy consisted
of three time points at which plasma samples could be drawn in each microdialysis
experiment in order to estimate the plasma exposure using the population priors.
2.2.7. In vitro probe recovery studies
To study our ability to dialyze erlotinib and OSI-420 as well as strategies required
to enhance their relative recovery through microdialysis probes, a stock solution
containing 1 μg/mL erlotinib and 0.5 μg/mL OSI-420 in artificial CSF (aCSF, Leggas et
al., 2004b) was prepared. A 1 mm microdialysis probe (MBR-1-5 brain probe, BASi, IN)
was inserted into this solution and perfused with: (a) aCSF, (b) 10% HPBCD in aCSF,
and (c) bovine serum albumin (BSA; 4% in aCSF) for 1 hour followed by 10% HPBCD
in aCSF. To assess the effect of flow rate on the recovery of erlotinib and OSI-420 from
the stock solution, perfusates were pumped through the probe at 0.3, 0.5, 1, and 2 μL/min
and dialysates were collected. Dialysates and stock solution samples were analyzed using
LC MS/MS. Relative recovery (%) was calculated as CDial/Cstock*100, where CDial is the
erlotinib or OSI-420 concentration in the dialysates and Cstock is the erlotinib or OSI-420
concentration in the stocks. All in vitro recovery experiments were performed at room
temperature under stirred conditions.
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2.2.8. Erlotinib brain microdialysis studies
In vivo microdialysis experiments were conducted to sample erlotinib and
OSI-420 in the ECF of the mouse brain after a single 50 mg/kg oral dose of erlotinib
suspended in 0.2% carboxymethylcellulose and 0.05% Tween 20. First, a microdialysis
guide cannula (MD-2255, Bioanalytical Systems- West Lafayette, IN) was inserted
vertically into the striatum in the cerebral cortex (1.1 mm anterior to bregma suture, 1.1
mm lateral to sagittal suture, 2.0 mm ventral). The surgery was performed under
anesthesia (100 mg/kg ketamine and 10 mg/kg xylazine) as previously reported (Shen et
al., 2009; Zhuang et al., 2006). Mice recovered for at least 3 days before the
microdialysis experiment. The day of the experiment, a 1-mm-length microdialysis probe
(MBR-1-5, BASi, IN) was primed and flushed with aCSF containing 10% HPBCD. The
newly primed probe was then slowly inserted in the guide cannula and allowed to
equilibrate for 1 hour at 0.5 µL/min. Under slight isoflurane anesthesia (2.5% in oxygen),
the mouse received a 50 mg/kg dose of erlotinib, by oral gavage. Then, dialysates were
collected for 24 hours, using a fraction collector CMA 142 (North Chelmsford, MA).
We used the limited sampling strategy described above to collect plasma samples.
At the end of the experiment, the animal was euthanized and the brain was fixed in 10%
neutral buffered formalin for 72 hours and embedded in paraffin. H&E-stained sections
(4 µm) were examined microscopically to examine the brain tissue surrounding the
cannula and probe.
2.2.9. In vivo microdialysis probe recovery using zero flow rate (ZFR) method
After the first 5 hours of sample collection, dialysates were collected at different
flow rates 0.2, 0.5, 1, and 4 µL/min. Dialysate concentrations were allowed to stabilize
for 10-15 min between each change. The recovery experiment lasted 2.5 hours after
which the flow rate was set back to 0.5 µL/min for the remainder of the experiment.
Samples were analyzed using LC MS/MS and concentrations were plotted against flow
rate. Extrapolation to zero flow rate was performed as previously described (Menacherry
et al., 1992) using non-linear regression analysis in GraphPad Prism version 5.0b
(GraphPad Software, San Diego, CA) using the following formula:
CDial=C0*exp (-rA*X)
where r (mass transport coefficient) and A (surface area of the dialysis membrane) are
constants, estimated using non-linear regression, C0 represents erlotinib or OSI-420
concentrations in the dialyzed tissue, CDial is erlotinib or OSI-420 concentration in
dialysates, and X is the flow rate at which the dialysate was obtained at different flow
rates. Since the microdialysis experiment was performed at 0.5 µL/min perfusion rate, in
vivo recovery was calculated as: CDial at 0.5 µL/min / C0 (Menacherry et al., 1992).
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2.2.10. Pharmacokinetic analysis of microdialysis studies
A pharmacokinetic model was fit simultaneously to the plasma and brain ECF
microdialysis data. In order to incorporate information from the previous plasma
pharmacokinetic experiment, pharmacokinetic data from both experiments was pooled
and analyzed together. Modeling was performed with NONMEM VII using the
importance sampling EM algorithm. The model was based on the model described above
for plasma data, with additional compartments for erlotinib and OSI-420 in brain ECF. In
addition to the previous parameters, this model included first-order rate constants
describing erlotinib transfer into and out of the brain ECF (k24 and k42), first-order rate
constants describing the transfer of OSI-420 into and out of the brain ECF (k35 and k53),
and a single volume of distribution parameter for erlotinib and OSI-420 in the brain ECF
(Vbrain). IIV was included on D1, CLERL/F, VERL/F, CLOSI/FE, VOSI/FE, and intercompartment rate parameters.
Individual post-hoc parameters were used to simulate the concentration-time
curve from 0 to 24 h in plasma and brain ECF for erlotinib and OSI-420 for each mouse
from which the area under the concentration-time curves for plasma and brain
(AUC0-24,Plasma and AUC0-24,Brain) were calculated with the log-linear trapezoidal method.
Unbound plasma AUC (AUC0-24,uPlasma) for erlotinib and OSI-420 were obtained by
multiplying AUC0-24,Plasma by the appropriate unbound fraction (fu). The extent of brain
penetration (PBrain) for erlotinib and OSI-420 was calculated as the brain ECF-to-unbound
plasma AUC ratio:
AUC
AUC

,
,

Differences in PBrain between wild-type mice and other mouse strains were assessed using
the Mann-Whitney test.
2.2.11. Intracellular drug accumulation studies
To study the role of several efflux and influx transporters in erlotinib intracellular
accumulation, we used an array of cell lines expressing specific efflux or influx
transporters and compared the accumulation of erlotinib or OSI-420 in the cell lines overexpressing each transporter to that transfected with an empty vector. Intracellular
accumulation of erlotinib and OSI-420 were measured in Saos2 cells transfected with
human BCRP or MRP4 and LLC-PK1 cells transfected with MDR1, in presence or
absence of the P-gp/BCRP inhibitor, elacridar.
Uptake experiments were done using HEK293 cells transfected with cDNAs
coding for members of human OCT, OAT, and OCTN families. Briefly, 5 x 105 cells of
each cell line were plated in 6-well plates in triplicates. Cells were allowed to attach
overnight. For cells expressing the OAT1, 2, 3, and their vector control, sodium butyrate
(5 µmol/L) was added to the medium for 24 h to induce expression of the respective
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transporter genes (Tahara et al., 2006). At the day of experiment, medium was removed
and cells were incubated with media containing 0.5 µg/mL of either erlotinib or OSI-420
at 37°C. At a predetermined time interval, the experiment was terminated by removing
the incubation medium and adding ice-cold PBS. Cells were washed twice with ice-cold
PBS, gently scraped, collected, and centrifuged for 4 minutes at 3000 rpm at 0°C.
Subsequently, cells were resuspended in 100 µL of 5 mM ammonium formate for cell
lysis. The BCA assay was used to determine protein concentrations. Erlotinib and
OSI-420 concentrations in the lysis supernatants were determined using LC MS/MS
(Zhao et al., 2003).
2.3.

RESULTS

2.3.1. Erlotinib and OSI-420 protein binding in mouse plasma
Using equilibrium dialysis, we assessed the extent of plasma protein binding for
erlotinib and OSI-420. The range of concentrations used was similar to those expected
after administering erlotinib orally to mice at 20 mg/kg. The time after which the dialysis
reached equilibrium was 10 hours. Erlotinib, as well as its metabolite, was found to be
highly protein bound in mouse plasma. Unbound fraction (fu) of erlotinib was 4.8% ±
0.7% and for OSI-420 was 6.6 % ± 0.7%. No significant differences were found in
unbound fractions of erlotinib or OSI-420 between strains (Table 2-1).
2.3.2. Limited sampling models for erlotinib and OSI-420
The erlotinib dosage used in preclinical studies has ranged from 5 to 150
mg/kg/day orally for up to 4 weeks (Marchetti et al., 2008; Sarkaria et al., 2007). In our
studies, we sought to use an erlotinib dosage that achieves a systemic exposure similar to
that observed in patients (Broniscer et al., 2009; Broniscer et al., 2007b). First, we
conducted a plasma pharmacokinetic study of a single erlotinib dose administered orally
at a dosage of 50 mg/kg in wild-type, Abcg2-/-, Mdr1a/b-/-, Mdr1a/b-/-Abcg2-/-, and Abcc4/mice. This single dose of erlotinib was tolerated well by all strains.
Between the different absorption models, a sequential zero-order and first-order
model described the data best based on goodness-of-fit plots and lowered the OFV
between 6 and 35 units for different strains compared to first-order absorption alone and
lowered the OFV between 9 and 33 units for different strains for zero-order absorption
alone. The final model is shown in Figure 2-1. Concentration-time plots for erlotinib,
OSI-420, along with the model-predicted concentrations are shown in Figure 2-2 and
Figure 2-3. Pharmacokinetic parameters for all strains are listed in Table 2-2.
The AUC0-24,Plasma in each strain was compared to wild-type mice. Mean
AUC0-24,Plasma for Abcg2-/-, Mdr1a/b-/-, Mdr1a/b-/-Abcg2-/-, and Abcc4-/- strains were 1.25,
0.9, 1.3, 0.9 fold compared to that of wild-type mice. Using the population parameters,
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Table 2-1.

Unbound fractions (fu) in plasma of different mouse strains
Strain
Wild-type
Abcg2-/Mdr1a/b-/Mdr1a/b-/-Abcg2-/Abcc4-/-

Erlotinib (fu)
5.24 ± 0.8
4.86 ± 0.1
5.59 ± 1.7
4.47 ± 0.09
4.58 ± 0.49
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OSI-420 (fu)
7.47 ± 1.75
8.08 ± 0.13
8.46 ± 0.91
7.33 ± 0.40
7.12 ± 0.41

Figure 2-1.

Compartmental pharmacokinetic model for erlotinib and OSI-420

D1, duration of zero-order absorption; ka, first-order absorption rate constant; VERL/F,
apparent volume of distribution of erlotinib; CLERL/F, apparent clearance of erlotinib;
VOSI/FE, apparent volume of distribution of OSI-420; CLOSI/FE, apparent clearance of
OSI-420; k24/k42, first-order rate constants of erlotinib in the brain extracellular fluid;
k35/k53 , first-order rate constants of OSI-420 in the brain extracellular fluid; VBrain,
apparent volume of distribution of the brain extracellular fluid.
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Figure 2-2. Plasma concentration-time plots of erlotinib and OSI-420 after oral
administration of a single dose of 50 mg/kg erlotinib
Model-fitted curves are represented for erlotinib (solid line) and OSI-420 (dashed line).
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Figure 2-3. Plasma concentration-time plots on linear scale of erlotinib and
OSI-420 after oral administration of a single dose of 50 mg/kg erlotinib
Model-fitted curves are represented for erlotinib (solid line) and OSI-420 (dashed line).
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Table 2-2.

Pharmacokinetic parameters for different mice strains
WT

Abcg2-/-

Mdr1a/b-/-

Mdr1a/b-/-Abcg2-/-

Abcc4-/-

D1 (hr-1)

2.74

0.6

0.82

2.33

0.806

Ka (hr-1)

0.21

0.049

0.19

0.12

0.202

CLERL/F (L.hr-1.Kg-1)

0.56

0.51

1.1

0.75

0.67

VERL/F (L. Kg-1)

0.006

0.0045

0.0009

0.021

0.0167

CLOSI/FE (L.hr-1.Kg-1)

1.07

0.95

1.5

0.549

2.14

VOSI/FE (L. Kg-1)

0.02

0.125

0.8

0.056

0.001

k24 (hr-1)

10

0.037

8.22

0.694

9.84

K42 (hr-1)

5.03

3.7

4.18

1.92

2.7

K35 (hr-1)

0.079

0.082

0.11

0.004

0.1

K53 (hr-1)

0.359

0.304

0.57

0.1

0.15

PK parameters
Model Parameters
(Unit)

Inter-individual variability (%CV)
D1

67.5

2.9

71.0

36.1

48.8

CLERL/F

43.4

2.5

56.8

9.6

89.5

VERL/F

36

43.2

48.2

72

44.6

CLOSI/FE

45.6

34.3

50.5

5

37.1

VOSI/FE

21.5

70.3

77.4

60.7

40.1

k24

27.6

27.5

29.8

28.2

91.9

K42

31.2

11.2

44.7

42.3

66.7

K35

16.7

21.8

19.6

50.7

71.2

K53

26.9

31.9

3.6

33.7

46.7
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Table 2‐2.

(continued)

PK parameters

WT

Abcg2-/-

Mdr1a/b-/-

Mdr1a/b-/-Abcg2-/-

Abcc4-/-

Residual Error (%CV)
Erlotinib

64.8

59.8

63.2

68

54.9

OSI-420

65.5

60.6

62.7

66.8

53.5
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we determined the optimal sampling time points to calculate the plasma AUC of erlotinib
and OSI-420, constraining to three time points over 18 h. The optimal time points were
similar in all strains: one early time point after the administration (5 min), one coinciding
with the plateau (range from 7.8 to 9 hours), and one late time point (18 hours). For the
ease of conducting the experiments, we chose to obtain plasma samples at 0.08, 8, and 18
hours from all strains.
2.3.3. In vitro microdialysis studies
Because reproducible dialysis of lipophilic drugs can be difficult using
conventional microdialysis methods (Loos et al., 2007; Wang et al., 2008), we anticipated
that the microdialysis of erlotinib would require the inclusion of an affinity-based
trapping agent, such as HPBCD, in the perfusate. Such modifications in the perfusate
have been used before to increase the recovery of poorly dialyzable drugs (Duo et al.,
2006). Results of our preliminary in vitro microdialysis experiments supported that
erlotinib and OSI-420 had relatively low relative recovery (1 and 2%, respectively) using
aCSF as a perfusate. The addition of 10% HPBCD in aCSF improved the recovery of
erlotinib and OSI-420 by ~ 8-fold (Figure 2-4).
Second, we tested the effect of different flow rates (0.3, 0.5, 1, and 2 µL/min) on
relative recovery. Increasing the flow rate yielded lower relative recovery. Lastly, we
evaluated the effect of perfusing the microdialysis tubes with 4% BSA to prevent the
binding of the drug to the tubes and thus improve the recovery. This strategy did not
improve the relative recovery and added complexity due to tube blockage and flow
resistance. Thus, we decided to use 10% HPBCD in aCSF at 0.5 µL/min at room
temperature for the in vivo microdialysis experiments to obtain sufficient recovery with
adequate sample volume (30 µL/h). The in vitro recovery at that flow rate was 18% ±
2.5% and 20% ± 1.3% for erlotinib and OSI-420, respectively.
2.3.4. Zero Flow Rate (ZFR) for estimation of in vivo recovery
To calculate erlotinib and OSI-420 concentrations in brain ECF, microdialysate
concentrations were corrected for probe recovery in each mouse using the ZFR method.
This method is based on the fact that at slow perfusion rates and steady state tissue
concentrations of the analyte, extrapolation to a hypothetical flow rate value of zero will
provide the absolute value of analyte in the dialyzed tissue (CECF) (Jacobson et al., 1985).
Probe recovery can then be calculated by dividing the concentration obtained at the flow
rate at which the experiment is conducted (i.e., CDial at 0.5 µL/min) by CECF. First, we
validated in vitro the use of the ZFR recovery method for recovery estimation. Dialysates
were collected from a stock containing 1 µg/mL of each erlotinib and 0.5 µg/mL OSI-420
at different flow rates and the concentrations were plotted against flow rate. The
estimated value of CECF in vitro obtained from extrapolation to zero flow rate using nonlinear regression was 96%±15% and 93%±12% for erlotinib and OSI-420, respectively
(results from 6 in vitro experiments; Figure 2-4). The ZFR requires that the concentration
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Figure 2-4.

In vitro microdialysis studies

A. Including 10% HPBCD in the perfusate increases recovery for erlotinib and OSI-420
as compared to aCSF alone.
B. In vitro validation of the zero flow rate method. Erlotinib and OSI-420 stocks (1000
and 500 ng/mL, respectively) were prepared; microdialysis probes were inserted in stocks
and perfused with 10% HPBCD in aCSF. Dialysates were collected at different flow rates
and concentrations were plotted against flow rate. CECF in vitro was estimated using nonlinear regression to a hypothetical zero flow rate.
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remain relatively constant while collecting the dialysates at different flow rates. Initial
microdialysis experiments (n=4) conducted under a stable flow rate of 0.5 µL/min
showed that brain ECF concentrations dropped by only 10-15% over the 5 to 8 hr period.
Assuming relatively stable target tissue concentrations, we decided to perform the
recovery experiment after 5 hours from drug administration. After the recovery
experiment, the flow rate was switched back to 0.5 µL/min and dialysates were collected
up to 24 hours. The in vivo recovery for erlotinib was 39% ± 13% and for OSI-420 was
24% ± 13%.
2.3.5. Increased ECF penetration of erlotinib and OSI-420 in Abcg2-/- and Mdr1a/b/Abcg2-/- mice
Using microdialysis, we sampled brain ECF from wild-type, Abcg2-/-, Mdr1a/b-/-,
Mdr1a/b-/-Abcg2-/-, and Abcc4-/- mouse strains after a single oral dose of erlotinib. Brain
penetration ratios are shown in Figure 2-5. In wild-type mice, PBrain (mean ± SD) for
erlotinib and OSI-420 was 0.27 ± 0.11 and 0.07 ± 0.02, respectively. Abcg2-/- mice
showed 5-fold higher erlotinib penetration (1.4 ± 0.9, p < 0.05, n=5) and 7-fold higher
OSI-420 penetration (0.51 ± 0.04, p < 0.05) than wild-type mice. However, neither
erlotinib penetration (0.49 ± 0.3) nor OSI-420 penetration (0.04 ± 0.02) was enhanced in
Mdr1a/b-/- mice (n=4, p > 0.05 for both). In the Mdr1a/b-/-Abcg2-/- mice, erlotinib brain
penetration was 0.7 ± 0.26, ~3-fold higher than in wild-type mice (p < 0.01, n=5), and
OSI-420 brain penetration (0.34 ± 0.21) was 4-fold higher (p < 0.01). Brain penetration
of Abcc4-/- mice was similar to wild-type mice for both erlotinib (0.32 ± 0.24, p > 0.05,
n=4) and OSI-420 (0.08 ± 0.06, p > 0.05). Histological examination verified the
localization of the probe track in the brain ECF and indicated no bleeding due to probe
insertion (Figure 2-6).
2.3.6. Intracellular accumulation experiments
Intracellular accumulation of erlotinib and OSI-420 was significantly reduced in
Saos2-BCRP cells as compared to Saos2-pcDNA3.1, indicating the significant role of
BCRP in erlotinib transport. Accumulation of OSI-420, but not erlotinib, in
LLCPK1-MDR1 cells was significantly reduced as compared to controls (LLCPK1
cells). Saos2-MRP4 cells did not show a significant difference in either erlotinib or
OSI-420 accumulation (Figure 2-7). Pre-incubation for 30 minutes with the specific P-gp
and BCRP inhibitor, elacridar significantly increased erlotinib and OSI-420 accumulation
in Saos2-BCRP cells (p <0.01), and OSI-420 accumulation in LLCPK1-MDR1 cells (p
<0.001) (Figure 2-8).
Furthermore, we sought to determine whether erlotinib is a substrate for influx
transporters using HEK-293 cells transfected with specific uptake transporters. Uptake of
erlotinib and OSI-420 was significantly higher in presence of organic anion transporter-3
(OAT3) (p <0.001) as compared to the HEK-293 cells transfected with empty vector.
Additionally, expression of the organic cation transporter-2 (OCT2) significantly
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Figure 2-5.
erlotinib

Brain penetration of erlotinib and OSI-420 after a single oral dose of

A. Penetration of unbound erlotinib and OSI-420 to brain ECF expressed as PBrain (mean
± SD from 4 to 7mice). *, P < 0.05 and **, P < 0.01, Mann–Whitney test of each
knockout model compared with wild-type mice.
B. Representative unbound erlotinib concentration-time plots in brain ECF (○) and
plasma (▲) in wild-type, Abcg2-/-, Mdr1a/b-/-, Mdr1a/b-/-Abcg2-/- and Abcc4-/- mice.
Model curves from individual predicted parameters are represented for plasma (dashed
line) and brain ECF (solid line).
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Figure 2-6. H&E staining showing the microdialysis cannula and probe track in
brain ECF with no gross pathological effect of 10% HPBCD on brain tissue
Blue dashes limit cannula track and red dashes limit probe track.
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Figure 2-7. Erlotinib and OSI-420 intracellular accumulation in vitro in cell lines
expressing efflux transporters
Time-course of drug accumulation in cell lines. Control, cells lines transfected with an
empty vector control; Transfected, cell lines transfected with a vector expressing the
indicated transporter; Transfected + Elacridar, transporter-transfected cells treated with 4
µM of the P-gp/BCRP inhibitor elacridar. Values are the percentage of the maximum
accumulation (mean ± SD; n=4-6) in control cells (Saos2-pcDNA for BCRP and MRP4
or LLC-PK1 for P-gp).
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Figure 2-8.
combined

Intracellular accumulation data from 15 min and 30 min time-points

*P < 0.001 as compared to accumulation in control cells (ANOVA with posthoc
Dunnet’s test).
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increased erlotinib and OSI-420 uptake (p <0.01) (Figure 2-9).
2.4.

DISCUSSION

Using microdialysis sampling, transporter deficient mice, pharmacokinetic
modeling, and cell lines transfected with efflux and uptake transporters, we elucidated the
roles of transport mechanisms involved in erlotinib disposition in brain parenchyma. Our
in vitro and in vivo data show that Bcrp1 is the primary efflux mechanism for erlotinib
and OSI-420 at the murine BBB, whereas P-gp and Mrp4 have little or no effect on
erlotinib CNS penetration. In vitro, intracellular accumulation of erlotinib and OSI-420
showed that only OSI-420, not erlotinib, accumulation was reduced in cells
overexpressing MDR1. The present study also showed that erlotinib and OSI-420 are
substrates for the human organic uptake transporter OAT3 and, to a lesser extent, OCT2.
Our technical approach of using microdialysis allowed the characterization of
unbound (active) erlotinib concentrations in brain ECF. Our technique overcomes the
limitations of (a) the CSF aspiration technique, which characterizes drug exposure in a
very specialized CNS compartment (Shen et al., 2009), and (b) the whole brain
homogenization technique, which does not discern between free and bound drug entities
or between different CNS compartments (brain parenchyma, CSF, and brain vessels). Our
study shows that the inclusion of HPBCD in the perfusate increases the recovery of
erlotinib, probably by including the drug into the core of the HPBCD molecule (Khramov
and Stenken, 1999b).
Although HPBCD proved indispensable for the detection of erlotinib and OSI-420
in the dialysate, its presence provided a challenge as we performed the recovery
experiments. Because HPBCD forms inclusion complexes with erlotinib in the perfusate
limiting drug movement to brain ECF, we could not use retrodialysis or no-net flux to
estimate in vivo recovery values. Instead, we chose to use ZFR method to estimate
recovery, realizing that as with all methods to calculate recovery, this approach has
limitations. For example, the ZFR method should be applied when the target tissue (e.g.,
brain ECF) is at a steady state. Our initial microdialysis experiments (n=4) conducted
under constant flow rate of 0.5 µL/min showed that brain ECF concentrations dropped by
only ~12% over the 5 to 8 hour period. Thus, we assessed recovery during a period 5 to 8
hours after the erlotinib dose was administered.
Because we calculated the recovery during this time interval (i.e., 5 to 8 hours),
we were only able to collect a single sample per flow rate. Although this short time frame
may not have allowed adequate time to achieve stable recoveries at each flow rate,
comparing in vitro recovery values obtained with either changing the flow rate or under
constant (i.e., stable) flow rate yielded similar recovery values suggesting that stable
recoveries can be achieved with our experimental approach (Table 2-3).
Our study has established that penetration of unbound erlotinib from plasma
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Figure 2-9. Transport of erlotinib, A and OSI-420, B by human organic ion
transporters
Results are shown for drug accumulation in HEK293 cells after 5 minutes incubation in
each cell line. Columns represent (mean ± SD) 8 to 18 observations per expressed
transporter, and are expressed as percentage of their respective control (white bar). Only
one control bar is shown for clarity purposes. The contribution of each transporter
towards erlotinib or OSI-420 uptake was established by comparing data obtained in
HEK293 cells overexpressing the transporter and HEK293 cells transfected with an
empty vector.* P < 0.05; ** P < 0.01; *** P < 0.001 versus control, one-way ANOVA
was performed followed by a post Dunnett test.
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Table 2-3.
In vitro recovery values (%) obtained while changing perfusion flow
rates in a similar fashion to in vivo experiment to recoveries obtained with stable
flow rate
Flow rate
(µl/min)
0.2
0.5
1

Recovery (%) with changing flow
rate
(mean ± SD of 5 experiments)
28.1 ± 2.2
16.2 ± 1.9
5.36 ± 2.7

Recovery (%) with constant
flow rate
(mean ± SD of 4 experiments)
32 ± 3
18.5 ± 2
7.3 ± 1.2

4

4.8 ± 1.4

4.2 ± 0.7

Similar recovery values shows ability to achieve stable recoveries during the ZFR
recovery estimation in vivo.
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across the BBB of wild type mice is limited (27%) and even lower for OSI-420 (7%).
Thus, even though OSI-420 exhibits anti-tumor activity (Meany et al., 2008; Moyer et al.,
1997), its low CNS penetration and systemic exposure (~10-20% that of erlotinib in
humans) suggest a minor role for OSI-420 in erlotinib clinical activity in brain tumors
(Broniscer et al., 2007b; Ling et al., 2006).
Our data show that Bcrp1 is the major efflux transporter limiting penetration of
erlotinib and OSI-420 into murine brain ECF. In vitro studies showed reduced erlotinib
and OSI-420 accumulation in Saos2-BCRP cells. Interestingly, a single nucleotide
polymorphism in the ABCG2 promoter that correlates with lower BCRP expression was
associated with higher erlotinib plasma exposure, indicating the important role of BCRP
in erlotinib disposition (Rudin et al., 2008).
Our results contrast with the conclusions by Kodaira et al stating that P-gp is the
major efflux transporter for erlotinib at the murine BBB (Kodaira et al., 2010). This
discrepancy can be explained by the different experimental designs used in each study. In
the latter study, the authors administered erlotinib via the jugular vein for 2 hours and
then analyzed erlotinib concentration in brain homogenates. They compared erlotinib
concentration in brain homogenates to that in plasma only at one time point (i.e., 2
hours), and did not account for erlotinib plasma protein binding. This study design has
several limitations. First, the homogenate technique could provide different results as it
describes drug accumulation in the whole brain rather than in specific compartments, and
second, relying on only one time point to determine the penetration ratio can mask the
whole exposure profile for erlotinib in plasma as it provides only a “snap shot” of the
penetration profile. In our study, we used the oral route for administering erlotinib to
mimic the clinical situation. Our studies also took into consideration the plasma protein
binding of both erlotinib and OSI-420.
While intracellular accumulation experiments showed that OSI-420 is a P-gp
substrate, OSI-420 brain penetration was not increased in Mdr1a/b-/- mice. This can be
due to the compensatory upregulation of Bcrp1 in Mdr1a/b-/- mice resulting in increased
overall drug efflux from the brain. Our group previously used semi-quantitative
immunohistochemical analysis to show that Bcrp1 is expressed at a higher level in the
brain of Mdr1a/b-/- mice than that in wild-type mice (Shen et al., 2009). This observation
agrees with previous study that shows 3 fold higher Bcrp1 mRNA in Mdr1a/b-/- mice
microvessels compared to wild-type mice (Cisternino et al., 2004).
In vitro screening of uptake transporters using HEK-293 transfected cells
identified erlotinib and OSI-420 as substrates for OAT3 and OCT2. The affinity of these
transporters for both anionic and cationic molecules has been previously reported (Ahn et
al., 2009; Arndt et al., 2001). While HEK-293/OCT2 cells showed significantly higher
erlotinib uptake, OCT2 contribution towards erlotinib uptake should be cautiously
interpreted given the ~40 fold higher expression of SLC22A2 gene, encoding OCT2, in
these cells (Filipski et al., 2008). Studying erlotinib disposition in Oct2-deficient mice
will clarify the affinity of OCT2 towards erlotinib.
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Our results could have clinical significance as Oat3 localized at the apical border
of the choroid plexus can restrict the penetration of its substrates in the CSF (Nagata et
al., 2002). Our group previously demonstrated that Bcrp1 and P-gp, localized apically at
the choroid plexus, pump their substrate, topotecan, in the CSF (Shen et al., 2009;
Zhuang et al., 2006). Thus, Oat3 can oppose the transport direction of P-gp and Bcrp1 at
the choroid plexus decreasing CSF drug accumulation. In rodents, Oat3 is predominantly
expressed at the basolateral border of brain endothelial cells where it has been implicated
in the brain to blood transport of its substrates (Kikuchi et al., 2003; Mori et al., 2003).
Further, OCT2 is expressed at the apical border of the endothelial cells and was shown to
increase the brain accumulation of their substrates (Lin et al., 2010).
Thus, in absence of Bcrp1 (i.e., in Abcg2-/- or Mdr1a/b-/-Abcg2-/- mice), the net
erlotinib ECF accumulation would be determined by the net effect of factors that favor or
oppose brain ECF penetration. Factors that favor erlotinib accumulation in the ECF
include OCT2 at the BBB and lack of Bcrp1 at the BBB (Figure 2-10). On the other
hand, Oat3 at the BBB and P-gp at the choroid plexus may restrict erlotinib accumulation
in brain ECF by moving the drug from the brain to the blood or the CSF as schematized
in Figure 2-10. This may explain the more than unity ECF accumulation for ABC
transporters substrates in Abcg2-/- and Mdr1a/b -/-Abcg2-/- mice observed in our study and
others (Kodaira et al., 2010; Kusuhara and Sugiyama, 2005; Lassman et al., 2005).
Another transporter of potential interest is the organic anion transporting polypeptide
(OATP2). OATP2 is expressed on both the apical and basolateral membranes of brain
endothelial cells and probably mediates the accumulation of its substrates across the
intact BBB vessels (Bronger et al., 2005; Gao et al., 1999; Kusuhara and Sugiyama,
2005). Further studies are warranted to identify the role of uptake transporters in erlotinib
CNS penetration.
Regarding the implications of our results on erlotinib elimination, OCT2 and
OAT3 transporters are abundantly expressed in the kidney (Bleasby et al., 2006). These
transporters may explain the renal clearance component of erlotinib elimination, which
accounts for ~10% of the overall elimination (Ling et al., 2006). However, transporters
expressed in the liver such as OAT2 and OCT1 were not found to transport erlotinib
indicating the involvement of other transport mechanisms such as OATP1B1 and
OAT1B3.
In conclusion, erlotinib is a Bcrp1 substrate whereas its metabolite is a substrate
for both P-gp and Bcrp1. Erlotinib brain ECF accumulation was restricted mainly by
Bcrp1. Intracellular accumulation studies confirmed the role of BCRP in erlotinib efflux
and the dual P-gp/BCRP inhibitor, elacridar, increased erlotinib accumulation in cells in
vitro. This study also indicates that erlotinib and OSI-420 are substrates for the uptake
transporters OAT3 and OCT2. Further study is warranted to assess the role of these
transporters in erlotinib brain accumulation. Our future experiments will focus on
studying the effect of ABC transporter inhibitors on erlotinib penetration in high-grade
glioma using genetically engineered animal models that recapitulate the genetics, the
biology, and the histology of human tumors.
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Figure 2-10.

Proposed model for the role of efflux and uptake transporters in erlotinib CNS penetration

A. Schematic diagram for endothelial cells with transporters localized on either apical border (facing blood) or basolateral
border (facing brain ECF).
B. Schematic diagram for the choroid plexus forming the BCSFB. Transporters are localized on either the apical border (facing
CSF) or basolateral border (facing blood). The arrows represent the direction of drug transporter.
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CHAPTER 3. MAGNETIC RESONANCE IMAGING (MRI)-GUIDED
MICRODIALYSIS CANNULA IMPLANTATION IN A SPONTANEOUS
HIGH-GRADE GLIOMA MURINE MODEL*
3.1.

INTRODUCTION

Cerebral microdialysis sampling is used to monitor CNS anti-cancer drug
disposition in mouse models (Boschi and Scherrmann, 2000). This approach provides
advantages over other sampling methods (e.g., whole tissue homogenization) including
sampling from discrete anatomic compartments such as the brain extracellular fluid
(ECF) or ventricular cerebrospinal fluid (vCSF) (Elmeliegy et al., 2011b; Shen et al.,
2009), sampling from normal brain or brain tumor tissue, and acquisition of unbound or
pharmacologically active drug moieties(Chaurasia et al., 2007). Furthermore,
microdialysis enables serial sampling from individual animals, thereby reducing the
number of animals required for pharmacokinetic investigations (Pan et al., 2007).
Microdialysis has been frequently employed in studying anti-cancer drug
penetration within brain tumors, particularly high-grade gliomas (Blakeley et al., 2009;
Carcaboso et al., 2010; Ma et al., 2003; Ma et al., 2001). These studies are most often
performed using murine orthotopic xenograft models in which human glioma cells are
stereotactically injected into a defined brain location and the microdialysis guide cannula
is simultaneously implanted. Tumor tissue then develops and surrounds the cannula
(Carcaboso et al., 2010; Ma et al., 2003; Ma et al., 2001).
Although orthotopic tumor xenograft models are easy to use, relatively
inexpensive, and reproducible, in many cases the genetics and histology of human tumors
are not adequately recapitulated (Richmond and Su, 2008). In addition, the tumor
microenvironment and host immune responses are likely altered in immune compromised
mice, which diminish the ability of xenograft models to truly recapitulate the features
observed in human tumors (Becher and Holland, 2006).
In contrast, genetically engineered murine models (GEMMs) of brain tumors
bestow many of the genetic and histological features of malignant human brain tumors
(Becher and Holland, 2006). In general, these mouse models develop tumors
spontaneously upon alteration of signaling pathways critical for the development of the
specific tumor of interest (Becher and Holland, 2006; de Vries et al., 2009). Thus,
molecular and other complex processes including specific contributions of the tissue
microenvironment, such as tumor angiogenesis, can appropriately mimic human disease
in these spontaneous tumor models.

*Reprinted with permission. Elmeliegy MA et al. (2011) Magnetic resonance imagingguided microdialysis cannula implantation in a spontaneous high-grade glioma murine
model. J Pharm Sci 100:4210-4214.
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In GEMMs, heterogeneous tumor growth patterns and development of tumors in
different brain regions pose several technical challenges to using these models for CNS
pharmacokinetic investigations (de Vries et al., 2009). For example, a major challenge to
using cerebral microdialysis to study anti-cancer drug penetration in tumors of GEMMs
is the difficulty of acquiring stereotactic coordinates to accurately place a microdialysis
cannula in the tumor. Traditionally, the coordinates of the intersection of the coronal and
sagittal sutures (bregma point) are used as a reference point for the placement of the
microdialysis cannula (Bert et al., 2004; Shen et al., 2009). However, this approach is not
practical in GEMMs because the bregma does not appear on images derived by MRI,
which is the imaging method used to identify the size and location of the spontaneously
arising tumors in the brain.
The objective of the current study was to use MRI imaging to identify a reference
point for implanting microdialysis cannula in spontaneously arising tumors in a GEMM
for high-grade glioma. The accuracy of cannula placement was verified by post-mortem
MRI and histological examination.
3.2.

MATERIALS AND METHODS

3.2.1. Animals
Transgenic mice used in this study were previously described (Chow et al., 2011).
Briefly, conditional deletion of Pten, Tp53, and Rb1 in Gfap-expressing cells was
induced by I.P injection of tamoxifen (Sigma, St. Louis, MO) to GFAP-CreERTM;
Ptenflox/flox;Tp53 flox/flox;Rb1flox/flox post-natal day 30 (P30) mice at a dosage of 9 mg/40 gm
weight daily for 3 consecutive days. Mice were maintained on a 12 h light/dark cycle
with free access to food and water. Mice developed tumors within 4 to 6 months. Other
mouse strains (C57BL6 and CD1 athymic nude mice) were also used for validation of
reference point studies. All animal studies were carried out in compliance with the
Animal Care and Use Committee at St. Jude Children’s Research Hospital.
3.2.3. Magnetic resonance angiography (MRA)
MRA data were produced from a Bruker FL2D Time-of-Flight (TOF) protocol
(TR 7.6 ms; TE 3.77 ms; Flip angle 90 degree). The raw data were acquired in the coronal
plane followed by Maximum-Intensity Projection (MIP) reconstruction on a Siemens
workstation using Syngo MR B15 software (Siemens, Erlangen, Germany). Image
processing procedures were similar for both angiography and post-mortem MRI studies.
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3.2.2. Magnetic resonance imaging (MRI)
MRI exams were performed using a 7-Tesla Bruker Clinscan animal MRI scanner
and a 4-channel phased-array surface coil (Bruker BioSpin MRI GmbH, Germany).
Animals were anesthetized using isoflurane during data acquisition. Turbo Spin Echo
protocols (TR 2000-2500 ms; TE 40 ms) were used to produce T2 weighted transverse
images with slice thickness of 0.5 mm. Turbo Gradient Spin Echo protocols (TR 2000
ms; TE 40 ms; Flip angle 180 degree) were used to produce fast T2-weighted images in
the coronal plane with slice thicknesses of 0.7 mm. For post-mortem MRI, the mouse
heads were submerged in Fluorinert FC-770 liquid (3M, Belgium) and imaged by a TSE
protocol with a rat head 4-channel phased-array surface coil.
3.2.4. Stereotactic surgery for microdialysis cannula insertion
The general surgical procedure has been previously described (Leggas et al.,
2004b). Briefly, a mouse was anesthetized with 50 mg/kg ketamine (Hospira, Inc., Lake
Forest, IL) and 10mg/kg xylazine (VEDCO, St. Joseph, MO). The head of the mouse was
fixed in position on a KOPF stereotactic apparatus (Tujunga, CA). A small incision on
the scalp was made and the rostral rhinal vein was identified.
Using MRI images, tumor coordinates were calculated using View-Dimensions
tool in Syngo MR B15 software. A microdialysis guide cannula was implanted in the
center of a tumor. The mouse was allowed to recover for 3–5 days. On the day of the
microdialysis study, a microdialysis probe (MBR-1-5, Bioanalytical Systems) was
inserted through the cannula. The probe was perfused with artificial cerebrospinal fluid
(aCSF, Leggas et al., 2004b) at 0.5 μL/min, and the probe membrane was allowed to
equilibrate for 1 hour before starting the microdialysis experiment. Microdialysis
experiments were performed as previously described (Elmeliegy et al., 2011b).
3.2.5. Histology
At the end of the microdialysis experiment, the animal was euthanized and the
brain was removed and fixed in 10% neutral buffered formalin for at least 24 hr. Cannula
and probe were removed and the brain was sliced into sagittal sections around the
location of the implanted cannula, dehydrated, cleared, and embedded in a paraffin block.
Sections were cut on a microtome at 4 µm thickness and every tenth section was
collected and stained with haematoxylin and eosin. All sections from a given block were
examined microscopically to verify the accurate placement of the microdialysis probe via
the track in the tumor.
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3.3.

RESULTS AND DISCUSSION

3.3.1. Identification of the rostral rhinal vein as a correlative reference point
Images of blood vessels of the mouse brain acquired using angiography revealed
the presence of a large vein overlying the border between the olfactory bulb and the
frontal lobe (Figure 3-1A and B). Using the mouse cerebral vasculature atlas (Dorr et al.,
2007), this vein was identified as the rostral rhinal vein, which is readily apparent to the
unaided eye and traverses both the dorsal and ventral surfaces following the olfactory
bulb/frontal lobe border (Figure 3-1C). The removal of skulls (n≥6 per strain used)
confirmed that this vein overlies the border between the olfactory bulb and the frontal
lobe. Thus, we designated our reference point as the intersection of the midline suture and
the rostral rhinal vein on the mouse brain surface. This point correlated with the
intersection between the midline and the olfactory bulb/frontal lobe border visualized on
T2-weighted MRI images of the brain. The rostral rhinal vein was present in all mouse
strains evaluated including C57BL6 and CD1 athymic nude. Anatomical dissection of
these strains confirmed that this vein overlies the olfactory bulb/frontal lobe border, thus
this method may be applied to target tumors in other mouse strains.
3.3.2. Determination of tumor coordinates and confirmation of probe placement
Tamoxifen injection induced Cre activity and spontaneous glioma formation in
GFAP-CreERTM;Ptenflox/flox;Tp53flox/flox;Rb1flox/flox mice (Chow et al., 2011). Induced mice
were monitored biweekly for tumor development by MRI using T2-weighted imaging
beginning at P120. Tumors developed in several locations within the brain including the
forebrain, midbrain, and the cerebellum. When a tumor was large enough for
microdialysis cannula/probe implantation (around 2.5-4 mm in diameter), placement
coordinates were determined using the View-Dimensions tool in Syngo MR B15
software. The X and Y axes were determined using the transverse plane (Figure 3-2A)
while the depth of implantation (Z-axis) was determined using the coronal plane (Figure
3-2B). Post-mortem MRI (Figure 3-2C and D) and immunohistochemical examination
(Figure 3-2E) confirmed targeted probe placement in all mice studied (n=6). Mice used
in this study developed tumors that arose within several regions of the brain including the
forebrain (33%), midbrain (50%), and the cerebellum (17 %).
3.4.

CONCLUSION

It is a challenge to accurately place microdialysis cannulae in GEMMs that
spontaneously develop brain tumors because the traditional reference point commonly
used to derive stereotactic co-ordinates for cannula implantation, the bregma, is not
visible by MRI. By using a combination of angiography and T2-weighted imaging by
MRI, we identified the rostral rhinal vein as a reference point to derive coordinates for
accurate placement of microdialysis cannula in tumors developing in several regions of
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Figure 3-1.

Presence of the rostral rhinal vein on the surface of a mouse brain

A. Angiogram of a non-tumor bearing GFAP-CreERTM; Ptenflox/flox; Tp53flox/flox;
Rb1flox/flox mouse showing a large vein across the olfactory bulb/frontal lobe border.
B. Diagrammatic illustration of veins on mouse brain surface illustrating the rostral rhinal
vein on the border between the olfactory bulb and the mouse brain frontal lobe.
Reproduced with permission from (Dorr et al., 2007).
C. Brain surface of a GFAP-CreERTM; Ptenflox/flox; Tp53flox/flox; Rb1flox/flox mouse. Lines
indicate location of the rostral rhinal vein.
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Figure 3-2. Derivation of MRI-guided stereotactic coordinates for cannula
implantation in spontaneously arising brain tumors
A. Transverse section on a T2-weighted MRI demonstrating a tumor in the left
hippocampus. Tumor margins are enclosed by a dashed line. The intersection between the
olfactory bulb/frontal lobe border and the midbrain was used as a reference point to
determine the coordinates on the Y-axis (a) and the X-axis (b).
B. Coronal section on a T2-weighted MRI for calculation of the depth coordinates, i.e.
Z-axis (c). In the provided example, values for a, b, and c were 7.6, 3, and 1.3 mm,
respectively.
C and D. Post-mortem MRI showing track of the microdialysis probe in the tumor in the
X and Y axes (red arrow), and on the Z-axis (yellow arrow).
E. Hematoxylin and eosin staining confirming probe location in the targeted area (yellow
dots limit tumor margins, blue dashes limit cannula track, and red dashes limit probe
track; lines were drawn with Adobe Photoshop V11.0).
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the mouse brain.
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CHAPTER 4. CEREBRAL MICRODIALYSIS FOR SIMULTANEOUS
SAMPLING OF TWO TYROSINE KINASE INHIBITORS IN AN
ORTHOTOPIC MOUSE MODEL OF GLIOMA
4.1.

INTRODUCTION

Anti-cancer drug penetration within brain tumors can be assessed using different
strategies including cerebral microdialysis (de Lange et al., 2000). This method provides
several advantages over brain tissue or tumor homogenization, including a significant
reduction in the number of animals required per study due to collection of multiple
samples per subject. Other advantages include providing compartment-specific
information about drug penetration and sampling of the unbound (pharmacologically
active) form of the drug. Cerebral microdialysis involves sampling of the target tissue
ECF (e.g., brain parenchyma, ventricular CSF, or tumor) via a semi-permeable probe
(Brunner and Langer, 2006). Perfusing the probe with a solution that mimics the
composition of the tissue ECF (i.e. perfusate) allows small molecules (e.g., anti-cancer
drugs) in the tissue ECF to diffuse across the semi-permeable membrane down their
concentration gradient. The collected samples (i.e. dialysates) can then be measured using
various analytical methods.
Microdialysis is commonly used to sample tissue ECF to assess the disposition of
a single anti-cancer agent per experiment. However, emerging therapies for brain tumors
include combining more than one targeted agent due to the highly resistant nature of
some cerebral tumors such as malignant glioma (Fan and Weiss, 2010; Karpel-Massler et
al., 2011; Krakstad and Chekenya, 2010). Thus, a robust method to sample multiple anticancer agents simultaneously coupled with adequate analytical methods can prove useful
in determining the penetration profile of multiple anti-cancer agents administered in
combination. To our knowledge, the technical feasibility of simultaneous sampling of
multiple anti-cancer agents via cerebral microdialysis has not yet been published.
One major limitation of microdialysis is the difficulty of sampling lipophilic
drugs (Benfeldt and Groth, 1998; Carneheim and Stahle, 1991). Such compounds are
generally highly-protein bound and thus only a small fraction of these compounds is
available for recovery through the microdialysis probe (Benfeldt and Groth, 1998).
Lipophilic compounds also tend to adhere to the polymeric materials of the microdialysis
probe and tubing. Such poor recovery represents a challenge against the use of
microdialysis to study the disposition of these lipophilic agents (de Lange et al., 2000).
Attempts to enhance recovery of lipophilic compounds involved adding BSA in the
perfusate, which reduces drug adsorption to microdialysis tubings (Carneheim and Stahle,
1991; Jensen et al., 2007). Despite the enhanced recovery, adding BSA can cause some
analytical challenges in sample cleanup for drug analysis using liquid chromatography
(Stenken et al., 2001).
The use of HPBCD has been proposed as an alternative to BSA to enhance the
recovery of lipophilic drugs (Duo et al., 2006; Khramov and Stenken, 1999a; b). We
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previously reported improved recovery of erlotinib upon including 10% HPBCD in the
perfusate (Elmeliegy et al., 2011b). In the present study, we tested whether addition of
this compound could improve the recovery of another tyrosine kinase inhibitor,
crenolanib (CP-868,596; AROG Pharmaceuticals). Crenolanib is an investigational drug
that specifically and potently inhibits PDGFRα and PDGFRβ (Lewis et al., 2009).
Currently, crenolanib is undergoing phase I trials for patients with either diffuse intrinsic
pontine glioma (DIPG) or recurrent high-grade glioma (HGG). Understanding the
penetration of crenolanib as a single agent and in combination with another tyrosine
kinase inhibitor, erlotinib in murine models of glioma will provide further insights into
the best use of these agents in regimens for treatment of brain tumors.
We conducted in vitro experiments to determine the appropriate conditions to
dialyze crenolanib and erlotinib, either alone or simultaneously. We then applied these
conditions to study crenolanib and erlotinib penetration as single agents or when
administered in combination in an orthotopic mouse model of glioblastoma.
4.2.

MATERIALS AND METHODS

4.2.1. Chemicals and reagents
Erlotinib and OSI-420 analytical standards, and their deuterated internal standard
used in the mass spectrometry assay were provided by OSI pharmaceuticals (Uniondale,
NY). HPBCD was purchased from CTD, Inc. (High Springs, FL). Crenolanib (CP868,
596 freebase, and its deuterated internal standard were supplied by Pfizer, New London,
Connecticut, USA).
4.2.2. Liquid chromatography/tandem mass spectrometry (LC MS/MS) method for
crenolanib determination in mouse plasma and CSF samples
Crenolanib and its deuterated form as an internal standard (ISTD) were separated
on a Pursuit 3µ Diphenyl column (Varian Inc., Lake Forest, CA; 50 x 2.0 mm) with a
mobile phase consisting of acetonitrile/10mM formic acid = 85/15/0.1. Samples were
processed using liquid-liquid extraction with t-butyl methyl ether. Extracted samples
were dried by nitrogen gas and reconstituted with Acetonitrile/10mM formic acid =
60/40/0.1. Detection was achieved by an API-5500 LC-MS/MS system (Applied
Biosystems, Carlsbad, California).
4.2.3

In vitro probe recovery

To evaluate probe recovery of crenolanib and erlotinib, stock solutions containing
30 ng/mL crenolanib, 30 ng/mL erlotinib, or 30 ng/mL of each in aCSF were prepared. A
1 mm microdialysis probe (MBR-1-5 brain probe, BASi, West Lafayette, IN) was
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inserted into each solution. The probe was perfused with: (a) aCSF or (b)
10%HPBCD/aCSF at 0.5, 1, 2, and 4 μL/min flow rate. Drug concentrations in each set
of dialysates and stock solution samples were analyzed using LC-MS/MS.
Concentrations were plotted against flow rate and extrapolation to a hypothetical ZFR
was performed as previously described (Menacherry et al., 1992) using non-linear
regression analysis in GraphPad Prism (GraphPad Software, San Diego, CA) using the
following formula:
CDial=C0*exp (-rA*X)
where r (mass transport coefficient) and A (surface area of the dialysis membrane) are
constants, estimated using non-linear regression, C0 represents drug concentrations in the
dialysed tissue, CDial is drug concentration in dialysates, and X is the flow rate at which
the dialysate was collected (Menacherry et al., 1992).
We then sought to determine whether the retrodialysis method, illustrated in
Figure 1-5, could be used to estimate probe recovery in presence of an affinity-based
trapping agent (HPBCD) in the perfusate. Thus, we perfused the probe with 30 ng/mL
crenolanib in 10% HPBCD/aCSF at 0.5 µL/min. The collected dialysate was then used to
determine the percentage of drug lost from the probe according to the following equation:
100

%

where Cperfused is crenolanib concentration in the perfusing solution i.e. 30 ng/mL and
Ccollected is crenolanib concentration measured in the collected dialysate.
On a separate experiment, we determined the percentage of drug gained from 30
ng/mL crenolanib stock solution when perfused with 10% HPBCD/aCSF at 0.5 µL/min
according to the following equation:
%

100

where Cdial is crenolanib concentration in the dialysate collected at 0.5 µL/min and
Cstock is crenolanib concentration in the stock solution, i.e. 30 ng/mL.
4.2.4. Tumor lines
Luciferase-labeled SJG2 glioma cell line was cultured in DMEM supplemented
with 10% fetal bovine serum from Invitrogen (Carlsbad, CA). This cell line was
generated from a 10-year old female diagnosed with malignant glioma at St. Jude
Children’s Research Hospital (Memphis, TN). This tumor line has been modified to
stably express firefly luciferase (Dickson et al., 2007). Luciferase-labeled SJG2 cell line
was used to generate the cranial orthotopic tumor model.
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4.2.5. SJG2 orthotopic tumor xenografts
8–12 week old CD1 athymic nude mice (Charles River Laboratories, Wilmington,
MA) were anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine. With the
guidance of a mouse brain atlas (Paxinos and Franklin, 2001), 5x105 SJG2 cells
suspended in 5 μL Matrigel (Becton Dickinson, Bedford, MA) were injected
stereotactically (David Kopf Instruments, Tujunga, CA) into the right caudate putamen.
A microdialysis guide cannula (MD-2255, Bioanalytical Systems, West Lafayette, IN)
was stereotactically implanted at the same coordinates of the tumor. Tumor growth was
monitored by bioluminescence (IVIS-100 imaging system, Xenogen, Alameda, CA
(Szentirmai et al., 2006). Briefly, mice were injected intraperitoneally with 120 mg/kg
D-luciferin firefly (potassium salt) (Caliper Lifesciences, Hopkinton, MA) and imaged
under isoflurane anesthesia after 5 minutes. All animal studies were carried out in
compliance with the Animal Care and Use Committee at St. Jude Children’s Research
Hospital.
4.2.6. Magnetic Resonance Imaging (MRI)
MRI exams were performed as previously described (Elmeliegy et al., 2011a).
Briefly, T2 weighted transverse images were generated with turbo spin echo (TSE)
protocols for transverse images and turbo gradient protocols for coronal plane using a
7-Tesla Bruker Clinscan (Bruker BioSpin MRI GmbH, Germany) from animals
anesthetized using isoflurane (2-3%). Images were read on a Siemens workstation using
Syngo MR B15 software (Siemens, Erlangen, Germany).
4.2.7. Determination of crenolanib protein binding in mouse plasma
Crenolanib was added to mouse plasma (Hiltop, Scottdale, PA) to make final
concentrations of 250 and 500 ng/mL. Crenolanib-spiked plasma (200 µL) was added to
each well of a 96-well equilibrium dialysis plate (Harvard Apparatus, MA) and incubated
on a rotator at 37°C. Samples were collected from plasma and PBS buffer chambers at
several time points after starting the experiment. Samples were analyzed using LC
MS/MS. Unbound fraction (fu) of crenolanib was calculated as follows:
u

PBS/ Plasma

where CPBS and CPlasma are the concentrations of crenolanib in PBS and plasma,
respectively.
4.2.8. Crenolanib and erlotinib steady state plasma pharmacokinetics
For animals receiving crenolanib or erlotinib as single agents, a 30 mg/mL
solution of either drug in DMSO was loaded in mini-osmotic pumps (Alzet, Model
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2001D; Durect, Palo Alto, CA) and subcutaneously implanted in CD1 nude mice. For
animals receiving both agents in combination, a solution containing 30 mg/mL of each
crenolanib and erlotinib, was loaded in the mini-osmotic pumps with subsequent
subcutaneous implantation. To determine the time required to achieve steady state,
plasma samples were taken by retro-orbital bleeding at 5 time points after drug
administration (3, 6, 12, 18, and 24 hours). At least three different animals contributed to
each time point. Blood samples were centrifuged at 3000 rpm for 3 minutes. Plasma was
immediately separated and stored at -80°C until further analysis using LC MS/MS.
4.2.9. Cerebral Microdialysis
Microdialysis experiments were performed in mice implanted with SJG2 cells 28
to 42 days after tumor implantation in tumors whose bioluminescence signal was ≥ 108
photons per second. On the day of the experiment, a microdialysis probe (MBR-1-5,
Bioanalytical Systems, West Lafayette, IN) was inserted through the cannula and
perfused at 0.5 μL/min flow rate with 10% HPBCD/aCSF. The probe membrane was
allowed to equilibrate for 1 h. Under slight isoflurane anesthesia (2.5% in oxygen), miniosmotic pump loaded with crenolanib only, erlotinib only, or both, was then
subcutaneously implanted. Dialysates were collected using a fraction collector CMA 142
(North Chelmsford, MA) at four different flow rates of 0.5, 1, 2, and 4 μL/min. Dialysate
concentrations were allowed to stabilize for 1 to 2 hours between each change. At least
two samples were collected at each flow rate. Dialysates were collected 6-8 hours after
pump implantation to ensure achievement of steady state in mouse plasma. Samples were
then analyzed using a previously described LC MS/MS method for erlotinib (Elmeliegy
et al., 2011b) and the above described LC MS/MS method for crenolanib. Erlotinib and
crenolanib concentrations were plotted against flow rate. Extrapolation to a hypothetical
ZFR was performed as previously described (Menacherry et al., 1992) using non-linear
regression analysis in GraphPad Prism (GraphPad Software, San Diego, CA) using the
following formula:
CDial=C0*exp (-rA*X)
where r (mass transport coefficient) and A (surface area of the dialysis membrane) are
constants, estimated using non-linear regression, C0 represents drug concentrations in the
dialyzed tissue, CDial is drug concentration in dialysates, and X is the flow rate at which
the dialysate was obtained at different flow rates.
To ensure achievement of steady state in plasma, at least two plasma samples
were obtained from each mouse during the microdialysis experiment. Unbound drug
concentrations in plasma were obtained by multiplying total drug concentration by the
appropriate unbound fraction (fu). The extent of tumor penetration (PTumor) was calculated
as a ratio between steady state tumor ECF concentration to-unbound plasma
concentration:
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where Tumor ECFss is the C0 obtained from non-linear regression of dialysate
concentrations obtained at different flow rates and Plasma SS is the average plasma
concentrations obtained from each mouse.
4.2.10. Statistics
Data are presented as mean ± SD. Mann-Whitney test was used for non-paired
comparisons of two groups of non-normally distributed data.
4.3.

RESULTS

4.3.1. HPBCD improves crenolanib recovery in vitro
Our previous experience with low probe recovery for erlotinib, a highly lipophilic
agent, led us to include the affinity-based trapping agent HPBCD in the perfusate to
improve crenolanib probe recovery, as crenolanib is also a highly lipophilic agent. In
vitro microdialysis experiments showed that crenolanib had relatively low relative
recovery of 12.2% ± 3.1% at 0.5 µL/min flow rate using aCSF as a perfusate. The
addition of 10% HPBCD in aCSF improved the recovery of crenolanib by ~ 2.4-4.2-fold,
depending on the flow rate (Table 4-1). Further, we tested the effect of different flow
rates (0.5, 1, 2, and 4 µL/min) on relative recovery. Increasing the flow rate yielded lower
relative recovery. Even with higher flow rates, crenolanib could be detected in all
microdialysis samples. Binding of crenolanib to microdialysis tubing was slightly
reduced when HPBCD was added to the perfusate (Table 4-2). Stock concentrations
estimated using non-linear regression analysis were within ±15% accuracy of the starting
concentration, indicating that ZFR was a suitable method for estimating probe recovery
for crenolanib (Figure 4-1) (Menacherry et al., 1992).
Retrodialysis method involves perfusing the probe with a known concentration of
the analyte under the assumption that the diffusion process is quantitatively equal in both
directions (i.e. percentage of drug lost from the probe = percentage of drug gained from
the medium to the dialysate) (Figure 1-5) (Wang et al., 1993a). Thus, we performed in
vitro microdialysis experiments to determine whether this assumption applies when
affinity-based trapping agents such as HPBCD are included in the perfusate. Using 10%
HPBCD/aCSF as a perfusate, the percentage of crenolanib lost was 3.2 ± 1.4 fold lower
than that recovered from the stocks [Drug lost (%) << Drug gained (%)]. Thus, the basic
assumption of retrodialysis method could not be verified using 10% HPBCD/aCSF
perfusate. Since we could not use retrodialysis, we used the ZFR method, which should
be applied at steady state conditions.
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Table 4-1.

In vitro recovery of crenolanib

Flow rate (µL/min)

aCSF

0.5
1
2
4

12.2% ± 3.1%
9.4% ± 1.5%
8% ± 3.4%
5.1% ± 1.3%

10% HPBCD/aCSF
(Relative recovery %)
52.4% ± 9.9%
36.5% ± 22.5%
19.3% ± 8.6%
12.4% ± 6.8%

Fold improvement
4.2
3.8
2.4
2.4

Microdialysis probes were inserted in a 30 ng/mL stock solution of crenolanib and
perfused aCSF or 10% HPBCD/aCSF. In vitro recovery values (%) were calculated as
CDial/Cstock*100, where CDial and Cstock are crenolanib concentration in the dialysates and
stocks, respectively. Data are reported as mean ± SD. Fold improvement was calculated
the ratio between the mean recovery value using 10% HPBCD/aCSF and aCSF.
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Table 4-2.

Binding of crenolanib to microdialysis tubings

Flow rate (µL/min)

aCSF

1

46.1% ± 8.6%

10% HPBCD/aCSF
(% bound to tubings)
23.7% ± 14.1%

Fold reduction in
drug binding
1.94

Stock solution of crenolanib (30 ng/mL) was prepared in aCSF or 10% HPBCD and
pumped through the microdialysis tubings. Samples are collected and crenolanib
concentrations in both the stocks and the collected samples are analyzed. Extent of
crenolanib binding to the tubing (%) was calculated as:
100

%

where Cstock is crenolanib concentration in the stock pumped in the tubings and
Ccollected sample is crenolanib concentration in the sample coming from the other end
of the tubings. Data are reported as mean ± SD of 3 observations at 1 μL/min. Drug
binding was not significantly different between groups (P = 0.1, Mann-Whitney test),
though there was a trend for reduced binding using 10% HPBCD/aCSF. Fold
improvement was calculated as the ratio between the mean % drug bound using 10%
aCSF and 10% HPBCD.
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Figure 4-1.

Validation of the ZFR method

Crenolanib stocks (30ng/mL) were prepared; microdialysis probes were inserted in stocks
and perfused with 10% HPBCD in aCSF. Dialysates were collected at different flow rates
and relative recoveries (%) were plotted against flow rate. CECF in vitro was estimated
using non-linear regression to a hypothetical zero flow rate to be 26.28 ng/mL (i.e.
87.46% of the nominal concentration of 30 ng/mL).
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4.3.2. Tumor growth kinetics and morphology
We studied crenolanib and erlotinib penetration in an orthotopically implanted
xenograft model of luciferase-labeled SJG2 glioma cells. The rate of engraftment of
SJG2 cells in CD1 nude mice was 85% (30/35). SJG2 tumors grew as mildly infiltrative
tumors invading through the brain parenchyma. These tumors were commonly associated
with the development of ventricular edema (Figure 4-2A). SJG2 tumors reached the
threshold bioluminescence signal, 108 photons per second, within 4-6 weeks postimplantation (Figure 4-2B), and neurologic signs were observed within 5 weeks.
4.3.3. Crenolanib and erlotinib steady state plasma pharmacokinetics
Determining the time required to achieve steady state in vivo is important in
designing the sampling strategy when using the ZFR method to calculate in vivo probe
recovery. We conducted a plasma pharmacokinetic study of crenolanib only, erlotinib
only, and crenolanib/erlotinib combination to determine the time required to reach steady
state drug concentrations in mouse plasma. Mini-osmotic pumps loaded with crenolanib,
erlotinib, or both agents in DMSO were subcutaneously implanted in CD1 nude mice at a
target dosage of 200 mg/kg/day. The drug release rate from these pumps is 240 µg/hr for
at least 24 hours. This dosage was well tolerated by the mice as visually observed by
normal respiratory rate, ability of the animal to defecate/urinate, regular access to food
and water, and absence of any neurological signs. Steady state levels of both crenolanib
and erlotinib were achieved within 6 hours post-implantation and were maintained for at
least 24 hours (Figure 4-3), as determined by comparing drug concentrations at 6 hours
to that at 3 and 24 hours. Plasma levels at 6 hours were significantly higher than at 3
hours (Mann-Whitney test, p < 0.05), but similar to that observed at 24 hours
(Mann-Whitney test, p > 0.2; Figure 4-3).
4.3.4. Crenolanib protein binding in mouse plasma
Using equilibrium dialysis, we assessed the extent of crenolanib protein binding
in mouse plasma. The concentrations used were similar to those expected after
administering crenolanib to mice at 200 mg/kg using mini-osmotic pumps (i.e., 250 and
500ng/mL). The time required to reach equilibrium was 18 hours. Crenolanib was found
to be highly protein bound in mouse plasma. Unbound fraction (fu) of crenolanib was
5.9% ± 0.5% and 6.1% ± 0.7% for the 250 and 500 ng/mL concentrations, respectively
(Figure 4-4).
4.3.5. Crenolanib penetration in SJG2 xenografts
We used cerebral microdialysis to sample crenolanib penetration in an orthotopic
mouse model of glioblastoma (i.e. SJG2). Crenolanib was administered as a single agent
subcutaneously using mini-osmotic pumps (target dosage 200 mg/kg). Using 10%
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Figure 4-2.

Growth characteristics of SJG2 tumors

A. T2-weighted MRI of two representative SJG2 tumors displaying invasive growth
pattern through the normal brain parenchyma with ventricular edema.
B. SJG2 tumor bioluminescence signal versus time. Data are presented as mean and SD
of 4-10 values per time point. Representative bioluminescence pictures are shown.
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Figure 4-3. Concentration-time profile for crenolanib, erlotinib, and OSI-420
after implantation of mini-osmotic pumps in CD1 nude mice
Concentrations obtained after single agent administration of crenolanib or erlotinib (red
lines) were similar to that obtained after administering both agents in combination (blue
lines) (p > 0.05). Steady state levels were achieved 6 hours post-implantation. Values for
steady state concentrations are reported on figure in ng/mL as mean ± SD of values
obtained at 6, 12, 18, and 24 hours.
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Figure 4-4.

Crenolanib is highly bound to plasma proteins

Crenolanib plasma protein binding assessed using equilibrium dialysis at two
concentrations (250 and 500 ng/mL). Unbound fraction (fu) was calculated as mean
values from 18, 24, and 36 hours.
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HPBCD/aCSF as perfusate and sensitive analytical methods, we were able to detect
crenolanib in dialysates. The mean ± SD for crenolanib penetration in SJG2 tumors was
PTumor= 0.19 ± 0.03, n=4 (Figure 4-5).
A second cohort of mice received crenolanib and erlotinib in combination (target
dosage of 200 mg/kg of each). Collected dialysates were split for analysis of crenolanib
and erlotinib/OSI-420. Crenolanib penetration in mice receiving crenolanib and erlotinib
(PTumor= 0.13 ± 0.05, n=6) was similar to that in mice receiving crenolanib alone
(Mann-Whitney, P = 0.07; Figure 4-5).
4.3.6. Erlotinib penetration in SJG2 xenografts
Erlotinib was administered as a single agent using mini-osmotic pumps (target
dosage 200 mg/kg). The mean ± SD of erlotinib penetration in SJG2 xenografts was
PTumor= 0.25 ± 0.03 n=4 (Figure 4-5). For the combination group, mice received 200
mg/kg of each crenolanib and erlotinib. In this group, erlotinib penetration (PTumor= 0.26
± 0.06, mean ± SD, n=6) was similar to that in mice receiving erlotinib alone
(Mann-Whitney, P = 0.47). OSI-420, the major erlotinib metabolite, was not detected in
the dialysates in any of the tested groups (single agent or combination) (Figure 4-5).
4.4.

DISCUSSION

Previous studies have reported irreproducible dialysis of lipophilic drugs
(Lindberger et al., 2002; Loos et al., 2007; Wang et al., 2008). In addition, previous
studies have only evaluated a single anti-cancer agent, an approach that has limited
relevance in light of the prevalent use of combinations of two or more anti-cancer drugs
in therapy. Here, we added the affinity-based trapping agent HPBCD to the perfusate to
increase microdialysis probe recovery of two lipophilic anti-cancer drugs, crenolanib and
erlotinib. We then used this method to determine crenolanib and erlotinib tumor
penetration as single agents or when administered in combination.
A major limitation of cerebral microdialysis is associated with the poor recovery
of lipophilic compounds due to the tendency of these compounds to stick to the sampling
probe and tubing components, poor solubility of these compounds in the hydrophilic
perfusate, and their high protein binding affinity which limits the unbound drug in the
sampling space (Benfeldt and Groth, 1998; Benveniste and Huttemeier, 1990; Carneheim
and Stahle, 1991; de Lange et al., 2000; Lindberger et al., 2002; Oravcova et al., 1996).
Several attempts to improve recovery of lipophilic compounds involved replacing the
commonly used hydrophilic perfusates with hydrophobic solutions such as 2.25%
glycerol in water or 20% soybean oil/ egg phospholipid (Intralipid®) which allow the
lipophilic drug to accumulate in the perfusate (Carneheim and Stahle, 1991; Kurosaki et
al., 1998). Other attempts involved adding BSA in the perfusate where the drug can bind
to BSA rather than the sampling device (Carneheim and Stahle, 1991). While these
approaches are often successful in improving the recovery of hydrophobic compounds,
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Figure 4-5.

Crenolanib and erlotinib penetration in SJG2 xenografts

Drugs were administered via mini-osmotic pumps. Tissue ECF was sampled via cerebral
microdialysis using 10%HPBCD/aCSF perfusate and using the ZFR recovery approach.
Mouse plasma samples were obtained via retro-orbital bleeding and corrected for protein
binding. Extent of tumor penetration (PTumor) was expressed as the ratio between tissue
concentration at hypothetical ZFR and unbound drug in mouse plasma. Tumor
penetration of unbound crenolanib and erlotinib after single agent or combination
administration of 200 mg/kg/day crenolanib, erlotinib, or both, via mini-osmotic pumps
in SJG2 mice. No statistical difference was observed in drug penetration between single
agent and combination groups, P > 0.05. Statistical analysis was performed using Mann
Whitney test.
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they add technical challenges during the experiment (i.e., flow resistance and tube
blockage, as well as analytical challenges during sample cleanup for LC-MS/MS assays)
(Elmeliegy et al., 2011b; Jensen et al., 2007; Sun and Stenken, 2003).
Another approach is the use of cyclodextrins in the perfusate (Khramov and
Stenken, 1999a; b). Cyclodextrins form complexes with lipophilic molecules by
capturing them in a non-polar central cavity (Loftsson and Brewster, 1996). Upon
including cyclodextrins in the perfusate, they form an inclusion complex with the analyte
on the dialysate side of the membrane reducing the effective concentration of the analyte
on the dialysate side. This results in a larger concentration gradient that facilitates more
diffusion from the target tissue to the dialysate which leads to higher recovery (Khramov
and Stenken, 1999a). Advantages of using HPBCD include its high safety profile (Gould
and Scott, 2005) and that it can be directly injected on the HPLC minimizing sample
processing prior to analysis (Italia et al., 1990; Maguire, 1987).
While including HPBCD in the perfusate proved technically indispensable in our
experiments, it also added some experimental challenges in estimating probe recovery.
During recovery estimation, HPBCD can form inclusion complexes with the drug
preventing its passage through the probe and thus all recovery estimation methods that
involve perfusing the probe with drug solution, e.g. retrodialysis, cannot be used to
estimate probe recovery should HPBCD be included in the perfusate. This mandates the
use of other recovery methods that do not involve drug perfusion through the probe.
These methods usually require constant drug concentrations while determining the
recovery, such as ZFR method (Elmeliegy et al., 2011b).
In vivo microdialysis experiments showed that crenolanib and erlotinib could be
simultaneously dialyzed and detected in the dialysates. However, we could not detect
OSI-420 in most of our microdialysis samples. We have previously reported that OSI-420
exhibits low penetration profile to mice brains (~7%) (Elmeliegy et al., 2011b). Since
average steady state concentrations of OSI-420 in mice plasma was 132 ng/mL (i.e. ~ 6
ng/mL of unbound OSI-420 in plasma), therefore OSI-420 concentrations in the brain
and that in the dialysates are expected to be below the LLOQ of our LC/MS-MS assay
(0.5 ng/mL).
We decided to use the steady state approach for dosing crenolanib and erlotinib
for two reasons. First, the ZFR recovery method, employed in these experiments due to
the presence of HBCD requires steady state drug levels at the target tissue. Second,
crenolanib has a shorter half-life in mice (t1/2 of crenolanib in CD1 nude
mice=0.53±0.11 hours, Dr. Clinton Stewart, unpublished data) than in humans (t1/2 of
crenolanib=14±4.18 hours) (Lewis et al., 2009). Clinical trials of either crenolanib or
erlotinib involve long-term chronic oral daily administration, which will result in steady
state drug concentrations in patient plasma (Broniscer et al., 2007c; Lewis et al., 2009).
Thus, studying CNS penetration of these drugs under steady state conditions in mice
could provide better recapitulation of the clinical situation.
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While the penetration of crenolanib to SJG2 tumors was similar between the
single-agent and combination administrations, overall crenolanib tumor penetration was
relatively low (PTumor=0.19 and 0.13), especially when compared to penetration of other
compounds in mouse models of glioma (Agarwal et al., 2011a; Carcaboso et al., 2010;
Vogelbaum et al., 2011; Wang et al., 2010; Zhou and Gallo, 2009). One possible
explanation is the relatively high molecular weight of crenolanib, 601.72 Daltons, which
may limit its passive diffusion through the BBB (Kniesel and Wolburg, 2000; Mahar
Doan et al., 2002). Another potential explanation could be active crenolanib transport
from brain to blood via efflux transporters at the endothelial cells of the BBB (Terasaki
and Ohtsuki, 2005). Finally, an intact BBB in SJG2 xenograft model might also limit
crenolanib penetration.
Despite the relatively low penetration of crenolanib in SJG2 tumors (mean ± SD
of crenolanib concentration in SJG2 tumors ECF was 2.55 ± 0.81 ng/mL n=4), PDGFRα
phosphorylation was inhibited in 66% (2/3) of SJG2 tumors treated with crenolanibloaded mini-osmotic pumps for 24 hours (data not shown). While 2.55 ng/mL of
crenolanib might be lower than crenolanib IC50 for PDGFRα determined using western
blot experiments (8.1 ng/mL) (data not shown), our experimental methodology could not
determine the concentration of free drug in the intracellular compartment. Given its high
lipophilic nature, crenolanib might accumulate in the intracellular compartment in
concentrations sufficient to inhibit PDGFRα activation.
In conclusion, cerebral microdialysis can be used to simultaneously sample
lipophilic anti-cancer agents. Inclusion of HPBCD increased probe recovery of
crenolanib and erlotinib. Sensitive analytical techniques are needed for successful
implementation of simultaneous sampling via cerebral microdialysis. This method will
increase our ability to conduct CNS penetration studies for multiple anti-cancer drugs
administered in combination.
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CHAPTER 5.

SUMMARY, DISCUSSION AND FUTURE DIRECTIONS

Primary CNS tumors, particularly malignant gliomas, represent a major
therapeutic challenge to basic scientists and neuro-oncologists. Despite decades of
research, hundreds of clinical trials, and aggressive treatment strategies, glioma patients
still suffer from poor prognosis, poor quality of life, and low overall survival (Broniscer
and Gajjar, 2004; Furnari et al., 2007; Wen and Kesari, 2008). Perhaps one of the most
important reasons for this poor prognosis is the intrinsic resistance of malignant glioma
achieved by effective DNA repair machinery (Frosina, 2009), deletion mutations in
several tumor suppressor pathways such as P53 and RB pathways (Paugh et al., 2010b;
TCGA, 2008), and simultaneous activation of multiple RTKs (Stommel et al., 2007;
TCGA, 2008). These genetic abnormalities maintain glioma cell survival, proliferation,
and stimulate its invasive growth pattern through the brain.
Another reason for the clinically challenging nature of malignant glioma is the
restricted delivery of anti-cancer agents to the active site in the brain, which is protected
by several barrier systems such as the BBB and the BCSFB. The overall objective of this
project was to better understand the CNS penetration of molecularly targeted agents
currently in clinical trials for treatment of malignant glioma using mouse models of
glioma.
While microdialysis offers several technical advantages to understanding CNS
drug penetration, it is not without limitations. One challenge to the use of microdialysis is
the low probe recovery of lipophilic compounds. The low recovery of these compounds
can be attributed to the tendency of these compounds to bind to the sampling
components, their poor solubility in hydrophilic perfusates, their high protein binding
affinity (which limits the unbound drug in the sampling space), and their tendency to
accumulate in the intracellular compartment, which reduces the sampling pool in tumor
ECF (Lindberger et al., 2002; Loos et al., 2007; Wang et al., 2008). This challenge is
particularly significant because many of the compounds under development for treatment
of brain tumors tend to exhibit lipophilic properties.
To address this issue we chose to include an affinity-based trapping agent
(HPBCD) in the perfusate to increase probe recovery of erlotinib and crenolanib, two
highly lipophilic agents. This resulted in an eight- and four-fold increase in probe
recovery for erlotinib and crenolanib, respectively. This approach has been successfully
applied to enhance probe recovery of several lipophilic agents such as gefitinib,
lapatanib, BEZ-235, and OSI-906 (data not shown). However, even with HPBCD in the
perfusate, we could not detect sirolimus, an mTOR inhibitor, in dialysates obtained from
U87-MG xenografts mouse models receiving 50 mg/kg sirolimus by oral gavage (data
not shown). This may be explained by the large molecular weight of sirolimus (914
Daltons), inability of HPBCD to form inclusion complex with sirolimus, or possibly due
to low sirolimus penetration in these tumors.
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While including HPBCD in the perfusate proved technically indispensable in our
experiments, it also added experimental challenges. During recovery estimation, HPBCD
forms inclusion complexes with the drug and thus recovery estimation methods that
involve perfusing the probe with drug solution, such as retrodialysis, could not be used to
estimate probe recovery. This mandates the use of other recovery methods (e.g., ZFR),
which require a constant drug concentration in the target tissue (Elmeliegy et al., 2011b).
Using HPBCD in the perfusate and the ZFR method for in vivo recovery
estimation, we studied erlotinib and OSI-420 penetration in control and transporterdeficient mice receiving erlotinib by oral gavage. We showed that Bcrp1 was the main
efflux transporter restricting erlotinib and OSI-420 penetration in mouse brain.
Intracellular accumulation studies confirmed the role of BCRP in erlotinib and OSI-420
transport. Furthermore, we showed that OSI-420 is a P-gp substrate while erlotinib is not.
OSI-420 is formed by removing one methyl group of erlotinib by CYP3A4. The different
transport profiles of erlotinib and OSI-420 by P-gp suggests that even this slight
structural difference between erlotinib and OSI-420 may affect the affinity of efflux
transporters to their substrates (Elmeliegy et al., 2011b).
BCRP and P-gp were shown to interact with several tyrosine kinase inhibitors.
Both transporters are expressed on the endothelial cells forming the BBB, the epithelial
cells of the choroid plexus forming the BCSFB, and on the glioma cell membrane. Thus,
they can influence the disposition of their substrates in different CNS compartments (i.e.,
vCSF, brain ECF, or inside tumor cells). Further, these transporters are highly expressed
in the small intestine and the colon and thus may reduce the oral bioavailability of their
substrates (Lemos et al., 2008).
While the contribution of efflux transporters to CNS disposition of anti-cancer
drugs has been extensively studied, the role of solute carrier transporters in CNS and
tumor cell uptake of anti-cancer agents remains unclear. We studied the intracellular
accumulation of erlotinib and OSI-420 using an array of HEK293 cell lines that over
express uptake transporters. Our data show that erlotinib and OSI-420 are substrates for
OAT3 and OCT2. We are currently planning studies to determine the contribution of
mouse Oct2 in erlotinib brain disposition using Oct2-/- murine models (Jonker et al.,
2003). Lower erlotinib accumulation in Oct2-/- mice would confirm the role of Oct2 in
erlotinib transport and indicate the potential importance of this transporter. These studies
can also provide further explanation for the high variability observed in erlotinib
pharmacokinetics in patients. Immunohistochemical analysis of various uptake and efflux
transporters will be conducted on mouse brain sections from wild-type and Oct2-/- mice to
identify any compensatory changes in transporter expression in Oct2 deficient mice.
We then sought to characterize erlotinib and crenolanib disposition in malignant
glioma using cerebral microdialysis. We decided to use a transgenic mouse model of
malignant glioma (conditional TKO) that highly recapitulates several features of the
human disease including tumor histology and genetic profiles. However, one limitation
against using these models in CNS penetration studies using cerebral microdialysis is the
inability to identify the bregma point on MRI. Thus, we identified a new reference point
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that relates the MRI scans to the mouse skull. This allowed accurate implantation of the
microdialysis guide cannula using MRI-derived coordinates.
Using this model, cerebral microdialysis studies to assess anti-cancer drug
penetration in transgenic models where tumors arise spontaneously can be performed.
This method can also be used to target catheters implanted stereotactically for local
delivery of anti-cancer agents within brain tumors, a technique known as convectionenhanced delivery. Convection-enhanced delivery involves insertion of a catheter directly
in the tumor where drugs are then locally delivered through the implanted catheter under
continuous pressure. This technique allows the delivery of high intratumoral drug
concentrations while reducing systemic side effects. However, accurate catheter
placement in the tumor is thought to be crucial for successful delivery of the anti-cancer
agent. Inadequate placement of the catheter was shown to cause fluid accumulation in the
subarachnoid space, which can be locally toxic. This is due to the high pressure required
for delivery of the drug in the tumor (Valles et al., 2009). Given the high success rate of
our method in identifying accurate stereotactic coordinates, our method can be applied to
accurately target catheters used in convection-enhanced delivery of anti-cancer agents in
novel preclinical models.
The use of appropriate preclinical models that reflect the genetic and histological
properties of the disease allows for better preclinical testing of novel anti-cancer agents.
Both spontaneous and xenograft models provide a set of advantages and disadvantages to
the research question. Spontaneous mouse models reproduce the microenvironment of
high-grade glial tumors better than xenograft models (Becher and Holland, 2006; Chow
and Baker, 2012; Kucherlapati, 2012). However, some concerns exist regarding the
practical application of these models in pharmacokinetic investigations given the long
latency for tumor development and the need for expensive imaging modalities to monitor
tumor growth. Furthermore, tumors that arise spontaneously display greater heterogeneity
compared to xenograft models. Indeed, we observed greater variability in tumor
penetration and contrast enhancement in the conditional TKO model compared to SJG2
xenografts (data not shown). This can be explained by the heterogeneous tumor growth
pattern, location, and histological representation of the tumor in conditional TKO model
while SJG2 tumors displayed more consistent growth pattern.
We observed higher crenolanib penetration in the conditional TKO compared to
that in SJG2 xenografts (data not shown). This may be explained by the contribution of
uptake transporters to crenolanib transport. Additional studies are warranted to
investigate the role of these transporters in crenolanib CNS disposition. Studies
investigating the role of solute carrier transporters in crenolanib CNS penetration should
study crenolanib intracellular accumulation in cell lines that overexpress uptake
transporters. Finally, the role of a particular transporter identified in the initial screen
should be further confirmed in mouse models deficient of that transporter. Identifying
efflux and uptake transporters responsible for crenolanib transport may provide further
explanation for the different crenolanib penetration profiles observed in transgenic and
xenografts models. The vastly different crenolanib penetration profiles in conditional
TKO and SJG2 xenografts indicates the importance of using more than one tumor model
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in drug penetration studies. Different transporters expression and vascular properties
among different models can drastically change drug penetration, and thus the use of a
single model may be misleading.
To achieve the required anti-tumor effect, tumor cells should be exposed to
effective concentrations of the anti-cancer agent for a sufficient duration. It is important
to emphasize that only the protein-unbound form at the active site is pharmacologically
available to interact with its target and exert a pharmacological effect. Anti-cancer drug
disposition within tumor compartments (vascular, extracellular, and intracellular) is
controlled by intricate properties of each compartment (Figure 5-1). First, only unbound
drug in plasma can diffuse across the BBB to accumulate within the tumor ECF. This
process is restricted by tight junctions between endothelial cells of the BBB and an array
of efflux and uptake transporters expressed on these cells. Unbound drug in tumor ECF
can then accumulate inside tumor cells. However, intracellular drug accumulation can be
influenced by efflux and uptake transporters expressed on glioma cell membranes
(Carcaboso et al., 2010). Finally, non-specific binding of the drug in the intracellular
compartment will further reduce the drug available to interact with its intracellular target
(Figure 5-1) (Baselga, 2006; Hammarlund-Udenaes, 2010; Hammarlund-Udenaes et al.,
2008; Reichel, 2009).
Unfortunately, methods for direct determination of unbound intracellular drug
concentration are not available. However, future experiments should rely on combining
several approaches to estimate unbound intracellular drug concentrations. HammarlundUdenaes and colleagues elegantly proposed an equation that can be used to estimate
unbound intracellular drug concentration in brain parenchyma (Hammarlund-Udenaes et
al., 2008). This equation can be possibly applied to estimate unbound intracellular drug
concentration inside tumor cells:
,

,

,

,

where Cu, cell is the unbound drug concentration in the intracellular compartment,
Atumor is the total drug in tumor, Vu,tumor is the unbound drug volume of distribution
in tumor (See text for explanation). Vtumor ECF and Vcell are the volumes of tumor
ECF and tumor cells, respectively, and can be substituted by physiological values of the
brain tissue and the astrocyte, respectively. Vu, cell is the volume of distribution of
unbound drug in tumor cell.
Vu, tumor describes the relation between Atumor and the unbound drug
concentration in tumor ECF regardless of tumor to plasma concentration ratio. Vu, tumor
can be calculated using the following equation:
,

,
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Figure 5-1.

Pharmacokinetic compartments of the CNS
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where Avascular is the amount of drug in tumor blood vessels which can be estimated as
previously described (Carcaboso et al., 2010) and Cu, ECF is the unbound drug
concentration in tumor ECF obtained from microdialysis experiments.
Atumor can be determined by tumor homogenization. We have previously used
the term Vu, tumor to account for the shift in drug accumulation from the ECF to the
intracellular compartment upon inhibiting efflux transporters (Carcaboso et al., 2010).
We have previously combined microdialysis and tumor homogenization methods using
steady state approach to determine Vu, tumor. Low Vu, tumor value indicates that the
drug is more confined to the ECF compartment (i.e. high Cu, ECF) with less intracellular
distribution while higher Vu, tumor value suggests that the drug exhibit more
intracellular distribution (Carcaboso et al., 2010). However, Vu, tumor does not account
for drug intracellular binding and thus cannot provide an estimate for the unbound drug
concentration in tumor cells. Homogenate binding experiments can be used to determine
the non-specific binding of the drug to the tumor. Determining intracellular binding will
allow estimation of Vu,cell. Thus, future experiments should combine different sampling
approaches (microdialysis, tumor homogenization, and homogenate binding) to estimate
the unbound drug concentration in the intracellular compartment (Cu, cell).
Several factors should be considered upon determining whether tumor penetration
of an anti-cancer agent in preclinical models is “adequate” for testing in patients with
malignant glioma. First, we should determine the unbound plasma systemic exposure that
can be achieved and tolerated in patients enrolled in phase I trials. Second, we should try
to recapitulate this exposure in preclinical models to determine whether the unbound drug
concentrations achieved in the tumor at this exposure are effective to exert a
pharmacological effect.
Upon conducting these studies, the extent of tumor penetration should not be
regarded as the only determinant of our decision on whether a certain agent is a good
candidate for clinical testing. For example, a drug with high potency against its target can
be effective despite its low tumor penetration. This is supported by our data that show
66% inhibition of PDGFRα in SJG2 xenografts by crenolanib despite its relatively low
tumor penetration in SJG2 xenografts.
Furthermore, in vitro and preclinical testing of potential agents should be
conducted at exposures similar to that achievable and tolerated in patients. Exerting a
pharmacological effect only at exposures that are 10 fold higher than that clinically
tolerated suggests a “no-go” decision for testing this drug in patients. In our experiments,
steady state concentrations in mouse plasma were ~ two-fold lower compared to
concentrations achieved in patients (Broniscer et al., 2009; Lewis et al., 2009). It is
important to note that we could not increase the dose administered in our studies as we
were limited by drug solubility in DMSO that was loaded in the mini-osmotic pumps.
Despite PDGFRα inhibition by crenolanib, downstream signaling events (e.g.,
AKT phosphorylation was not affected) (data not shown). This agrees well with previous
reports showing redundant signaling of multiple RTKs, such as PDGFR and EGFR, to
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maintain active PI3K signaling in malignant glioma (Stommel et al., 2007). These studies
indicate the need for combination regimens to inhibit PI3K pathway and alter glioma
survival. Thus, we designed studies in which we combined PDGFR and EGFR inhibitors
in our SJG2 xenografts and studied their tumor penetration using cerebral microdialysis.
Using HPBCD in our perfusate, ZFR method to estimate in vivo probe recovery, and
sensitive analytical techniques, we showed, for the first time, the feasibility of
simultaneous sampling of multiple anti-cancer agents via cerebral microdialysis. Future
studies should evaluate the effects of this combination on downstream Akt signaling at
exposures achievable in the tumors. Our method will enable better understanding of CNS
penetration of several drug combinations. Using our method, tumor penetration of several
combinations targeting pathways known to maintain glioma survival should be evaluated.
Such combinations may include agents that target multiple components of the same
pathway (e.g., PDGFR, Akt, and mTOR inhibitors) or those targeting several pathways
(e.g., PDGFR and MEK inhibitors).
In conclusion, we developed new techniques to improve microdialysis probe
recovery of erlotinib and crenolanib. We identified efflux and uptake transporters that
regulate erlotinib CNS disposition. We developed an MRI-guided method to implant
microdialysis cannula in a spontaneous glioma murine model. We identified suitable
microdialysis conditions used to sample multiple anti-cancer agents in tumor ECF of
mouse models of glioma.
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